A BACILLUS STRAIN AND METHODS FOR ITS USE IN PROMOTING PLANT GROWTH

Abstract

The present invention relates to a composition comprising a biologically pure culture of the Bacillus spp. strain NRRL B-67746 and mutants of that strain having all the identifying characteristics of the strain. The present invention also provides a method for promoting plant growth, wherein the method comprises applying said strain or mutants to the plant, a part of the plant, and / or a locus of the plant.

Description

A BACILLUS STRAIN AND METHODS FOR ITS USE IN PROMOTING PLANT GROWTH q Lznnn / zznz / E / YiAi REFERENCE TO RELATED APPLICATIONS This application claims priority over U.S. provisional patent application no. 62 / 865,823, filed on June 24, 2019, the full content of which is incorporated herein by reference in its entirety. REFERENCES TO THE LIST OF SEQUENCES PRESENTED ELECTRONICALLY The official copy of the sequence list was submitted electronically via EFS-Web as an ASCII sequence list in a file named “BCS199001_WO_ST25.txt” created on Wednesday, June 3, 2020, with a size of 3 kilobytes, and is submitted concurrently with the specification. The ASCII sequence list contained in this document is part of the specification and is incorporated herein by reference in its entirety. FIELD OF TECHNOLOGY The present invention relates to the field of bacterial strains and their ability to improve plant health, including yield. BACKGROUND In crop protection, there is a continuous need for applications that improve plant health. Healthier plants generally result in higher yields and / or better quality of the plant or its products. Furthermore, due to their increased vigor, healthier plants exhibit better resistance to biotic and / or abiotic stress. To promote plant health, fertilizers, both organic and inorganic, are used worldwide. A fertilizer can be a single substance or a mixture, and it is used to provide nutrients to plants. A significant achievement in fertilizer application was the development of nitrogen-based fertilizer by Justus von Liebig around 1840. However, fertilizers can cause soil acidification and destabilize the soil's nutrient balance, including mineral depletion and the enrichment of salts and heavy metals. Furthermore, excessive fertilizer use can lead to disruption of soil fauna, as well as pollution of surface and groundwater. Additionally, harmful substances such as nitrate can accumulate in plants and fruits. One possible alternative to fertilizer for enhancing plant growth is plant-associated bacteria such as rhizobacteria. These bacteria are associated with many or all plant species. The mechanism behind the effect of plant-associated bacteria on plant growth is still open to speculation. Ryu et al. (Proc. Nati. Acad. Sci. USA

[2003] 100, 4927-4932) suggested that, among the root-colonizing rhizobacteria, some strains regulate plant growth through the release of 2,3-butanediol and / or acetoin. There remains a need to provide alternative means to enhance plant growth and improve plant health. This includes a need for highly effective rhizobacteria that promote plant growth and related fermentation products. COMPENDIUM To meet this need, the applicants developed plant growth-promoting rhizobacteria with extraordinary plant growth-promoting capabilities: Bacillus spp. NRRL B-67746. The present invention relates to compositions comprising Bacillus spp. NRRL B-67746. The invention also comprises mutants of this strain that have all the identifying characteristics of the original strain. These compositions are biologically pure cultures of the original or mutant strain. In some instances, these mutants improved the ability to promote plant growth compared to the Bacillus spp. NRRL B-67746 strain. In some respects, the mutant strains have over 90% sequence identity with the Bacillus spp. NRRL B-67746 strain. In other respects, the mutant strains have at least approximately 98% sequence identity with the 16S rRNA sequence of B-67746. In some instances, the compositions are fermentation products of the Bacillus spp. NRRL B-67746 strain or mutants thereof. In other respects, the fermentation product is a lyophilized powder or a spray-dried powder. In certain aspects, the fermentation product also comprises a formulation ingredient. The formulation ingredient may be a wetting agent, a diluent, a solvent, a spontaneous growth promoter, an emulsifier, a dispersant, a frost protectant, an osmoprotectant, a thickener, a spore nutrient initiator, and / or an adjuvant. In one embodiment, the formulation ingredient is a thickener. In yet another aspect, the fermentation product is a fluid suspension. The present invention also provides a method for treating a plant to enhance plant growth by applying to the plant, a part of the plant, and / or a locus, the plant strain q Lznnn / zznz / E / YiAi Bacillus spp. B-67746 or a mutant thereof, or a composition comprising the Bacillus spp. B-67746 strain or a mutant thereof. The composition may be a fermentation product of the Bacillus spp. B-67746 strain or a mutant thereof. In yet another aspect of this embodiment, the composition also comprises a carrier suitable for agriculture, such as a formulation ingredient. In other embodiments, the method involves applying the composition to the seed of a plant. In other respects, useful plants are selected from the group consisting of soybeans, corn, sorghum, cotton, wheat, canola (oilseed rape), and sugar beet. In yet another aspect, the composition comprises a plant seed coated with a Bacillus spp. B-67746 strain or a mutant thereof. In one embodiment, the strain is applied to approximately 1 × 10⁵ to approximately 1 × 10¹⁰ colony-forming units (CEU) per seed of the Bacillus spp. B-67746 strain or a mutant thereof. DETAILED DESCRIPTION Bacillus spp. NRRL B-67746 is a rhizobacteria isolated from field trials evaluating disease management in cotton in the USA. Bacillus spp. NRRL B-67746 is also known as AP211. Standard assays were conducted to determine that NRRL B-67746 produces siderophores and indoleacetic acid, enhances nitrogen assimilation and uptake, and is present in soybean nodules. These properties are indicative of plant growth-promoting properties. For example, siderophore production can lead to improved iron availability in plants associated with the bacteria, as siderophores can chelate iron, thus making it available for plant uptake. Furthermore, plants use phytohormones, such as auxins, including IAA, to influence cellular function.Some studies have shown a positive correlation between microbial IAA production and plant growth. See Shahab, S., et al., “Indole Acetic Acid Production and Enhanced Plant Growth Promotion by Indigenous PSBs,” African Journal of Agricultural Research, Vol. 4 (11), (November 2009), 1312–1316; see also Marques, A., et al., “Assessment of the Plant Growth Promotion Abilities of Six Bacterial Isolates Using Zea mays as Indicator Plant,” Soil Biotechnology and Biochemistry, 42 (2010), 1229–1235. NRRL B-67746 was identified as a Bacillus strain by 16S ribosomal RNA sequencing. The 16S ribosomal DNA sequence for NRRL B-67746 is provided as the SEQ ID Ns: 1. Analyzes of the complete genome sequence for NRRL B-67746 revealed that the strain is q Lznnn / zznz / E / YiAi part of the Bacillus operational group, as described in Fanyolique B., et al., “Bacillus amyloliquefacíens, Bacillus velezensis, and Bacillus siamensis Form an “Operational Group B. amyloliquefaciens” within the B. subtilis Species Complex,” Front Microbiol, vol. 8, p. 22 (2017). It was also determined according to the complete genome sequence that NRRL B-67746 is a Bacillus velezensis. NRRL B-67746 was cultured in the laboratory, and the resulting fermentation product was screened against other fermentation products from several additional rhizobacteria. Compositions based on NRRL B-67746 exhibit unique and superior plant growth-promoting properties compared to other Bacillus spp. strains in the Bacillus amyloliquefaciens operating group and were therefore selected for further development. Details of these trials and comparisons are provided in the Examples section. The term “plant growth promotion” or “plant growth-promoting,” as used herein, refers to the ability of a microorganism to exert a beneficial effect on plant growth, development, or crop yield. For example, this may relate to an increase in length, total surface area, and / or fresh and / or dry weight of the roots and / or shoots of treated plants or crops compared to untreated plants or crops. Other indications of a beneficial effect on plant growth include increased nodulation in soybeans, an increase in total fine root length, and an increase in root branching. Plant growth promotion can also be characterized by an increase in plant vigor, including the following: (a) improved plant vitality, (b) improved quality of the plant and / or plant products, e.g. e.g., improved protein content, (c) improved visual appearance, (d) delayed senescence, (e) improved root growth and / or more developed root system (e.g., as determined by root dry mass), change in root architecture, (f) improved nodulation, particularly rhizobian nodulation, (g) longer panicles, (h) larger leaf blade, (i) fewer dead basal leaves, (j) increased chlorophyll content, (k) increased nitrogen balance index, (i) decreased anthocyanins, (m) prolonged photosynthetically active period, (n) increased or improved stand density, (o) less lodging, (p) increased plant weight,(q) increased plant height, (r) increased tillering, (s) stronger and / or more productive shoots, (t) fewer unproductive shoots, (u) improved photosynthetic activity and / or improved pigment content, therefore, greener leaf color, (v) earlier and / or improved germination, (w) improved and / or more uniform and / or earlier emergence, (x) greater shoot growth, (y) earlier flowering, (z) earlier fruiting, (aa) earlier grain maturity, (ab) less fertilizer required, (ac) less seed required, (ad) improved association with beneficial symbionts such as mycorrhizae, (ae) improved grain size and / or filling, as in maize or wheat, (af) increased nutrient uptake or tolerance to environmental stress, and (ag) improved plant nutrient uptake and / or water absorption. According to the present invention, “yield increase” of a plant, particularly an agricultural, forestry, and / or ornamental plant, means that the economic yield of a product of the respective plant (seed, tuber, leaf, flower) is increased by a measurable amount over the yield of the same plant product produced under the same conditions, but without the application of the composition of the invention or without the application of an original bacterial strain, such as Bacillus spp. NRRL B-67746 or a mutant thereof. According to the present invention, it is preferred that the yield increase be at least 0.5%, or at least 1%, or at least 2%, or at least 4%, or at least 5%, or at least 10% compared to suitable controls.Plant growth-promoting ability refers to the ability of a strain to enhance one of the properties mentioned above in a plant after application to a plant, part of a plant, or locus of a plant compared to a plant that has not been treated with the plant growth-promoting strain.In one embodiment, the strains of the present invention increase the yield or total weight of the plant by at least approximately 0.5% or at least approximately 1% or at least approximately 2% or at least approximately 3% or at least approximately 4% or at least approximately 5% or at least approximately 6% or at least approximately 7% or at least approximately 8% or at least approximately 9% or at least approximately 10% or at least approximately 11% or at least approximately 12% compared to plants produced under the same conditions but without treatment with a plant growth-promoting strain or without the application of Bacillus spp. NRRL B-67746 or a mutan thereof. The present invention also provides mutants of the Bacillus spp. strain NRRL B-67746 with improved plant growth-promoting properties and methods for generating, screening, and developing such mutants. The term “mutant” refers to a genetic variant derived from the Bacillus spp. strain NRRL B-67746. In one embodiment, the mutant has one, more, or all of the identifying (functional) characteristics of the Bacillus spp. strain NRRL B-67746. In one particular instance, the mutant or a fermentation product thereof improves plant health, including yield. Such mutants may be genetic variants that have a genomic sequence that has more than approximately 85%, more than approximately 90%, more than approximately 95%, more than approximately 96%, more than approximately 97%, more than approximately 98%, or more than approximately 99% sequence identity with NRRL B-67746.In another instance, such mules may have a 16S rDNA sequence that has at least approximately 98%, at least approximately 99%, or at least approximately 100% sequence identity with the 16S rDNA sequence of NRRL B67746. The mutant strain can be any strain of the mutant that has one, more, or all of the identifying characteristics of the Bacillus spp. strain NRRL B-67746 and, in particular, plant growth-promoting activity that is superior to any one or more of such strains. In yet another embodiment, the mutant produces more indoleacetic acid (“IAA”) than the original strain. Mutants can be obtained by treating cells of the Bacillus spp. NRRL B-67746 strain with chemicals or irradiation, or by selecting spontaneous mutants from a cell population of said Bacillus spp. NRRL B-67746 strain (such as phage-resistant mutants or antibiotic-resistant mutants), by genomic shuffling, as described below, or by other means well known to those skilled in the art, such as gene editing. Genomic shuffling among Bacillus strains can be facilitated through a process called protoplast fusion. This process begins with the formation of protoplasts from vegetative bacillus cells. The removal of the peptidoglycan cell wall, typically using lysozymes and an osmotic stabilizer, results in the formation of a protoplast. This process is visible under a light microscope as spherical cells. The addition of polyethylene glycol (PEG) then induces fusion between the protoplasts, allowing the genetic contents of two or more cells to come into contact, thus facilitating genomic mixing and recombination. The fused cells are then partitioned and coated onto a solid growth medium. During recovery, the protoplasts reconstruct their peptidoglycan cell walls and revert to a bacillus shape. See Schaeffer, et al., (1976) PNAS USA, vol. 73, 6:2151-2155). q Lznnn / zznz / E / YiAi In one embodiment, the method for obtaining the mutants includes generating mutants and then screening these mutants to increase plant growth promotion compared to the original strain. In one embodiment, the yield of the plant, crop, fruit, or vegetable, or the plant mass from materials treated with the mutant strain, is increased by approximately 1% to approximately 10%, by approximately 2% to approximately 15%, or by approximately 2% to approximately 20% compared to the yield of the plant, crop, fruit, or vegetable, or the plant mass from materials treated with the original strain.In yet another aspect, the yield of the plant, crop, fruit or vegetable of materials treated with the mutant strain increases by approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 10%, approximately 20%, approximately 30%, compared to an untreated plant, crop, fruit or vegetable or compared to a plant, crop, fruit or vegetable treated with the wild type strain. In another embodiment, these mutants can then be screened for increased production of various plant growth regulators, such as IAA, gibberellin, or cytokinin; increased production or activity of 1-aminocyclopropane-1-carboxylate (ACC) deaminase or superoxide dismutase; increased production of bacterial compounds that contribute to induced systemic resistance in plants, such as siderophores, salicylic acid, and lipopolysaccharides; and / or increased plant growth-promoting capacity compared to the original strains. Multiple rounds of mutagenesis, with and without inter-round screening, can be used to generate and screen mutants. Fermentation products from mutants with one or more enhanced attributes can be produced and applied to plants to promote growth. In a method according to the invention, a composition containing Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant of the above-mentioned strain can be applied to any plant or any part of any plant growing in any type of growing medium (e.g., soil, vermiculite, shredded cardboard, and water) or can be applied to plants or parts of plants growing aerially, such as orchids or ferns. The composition can be applied, for example, by spraying, atomizing, vaporizing, dispersing, dusting, watering, irrigating, sprinkling, pouring, or fumigating. As indicated above, the application can be carried out in any desired location where the plant of interest is placed, such as in agricultural, horticultural, forest, plantation, orchard, nursery, organic farming, lawn and urban environments. The strains and compositions of the present invention can be applied to the seed, plant, or plant parts as a powder, aqueous solution, or non-aqueous solution. The powders can be dry, wettable, or water-dispersible granules. In some embodiments, the spore-forming bacteria is a solution, an emulsifying concentrate, a wettable powder, a suspension concentrate, a soluble powder, granules, an emulsion-suspension concentrate, natural and synthetic materials impregnated with active compounds, and fine-release capsules. The strains and compositions of the present invention, in liquid or dry form, can be mixed with the soil before, during, or after planting. In one embodiment, the composition is in a liquid state and is mixed with the soil before or during planting. The compositions of the present invention include biologically pure cultures of the strains described herein. Biologically pure cultures of Bacillus spp. NRRL B-67746 and mulants derived therefrom can be obtained using methods well known in the art, including the use of the media and other methods described below. Conventional large-scale microbial culture processes include submerged fermentation, solid-state fermentation, or liquid surface culture. During fermentation, as nutrients are depleted, the cells begin the transition from the growth phase to the sporulation phase, so that the final product of fermentation is largely spores, metabolites, and residual fermentation medium. Sporulation is part of the natural life cycle of Bacillus spp. and is generally initiated by the cell in response to nutrient limitation.Fermentation is designed to obtain high levels of colony-forming units and to promote sporulation. The bacterial cells, spores, and metabolites in the culture medium resulting from fermentation can be used directly or concentrated using conventional industrial methods such as centrifugation or filtration, including tangential flow or depth filtration, and evaporation. The compositions of the present invention include the products of the microbial culture processes described herein. In embodiments where submerged fermentation is used as the culture process, the product is referred to as “fermentation broth.” Such broth may be concentrated, as described above. The concentrated fermentation broth may be washed, for example, by means of a diafiltration process, to remove residual fermentation broth and metabolites. The term “concentrated broth,” as used herein, refers to fermentation broth that has been concentrated by conventional industrial methods, as described above, but remains in liquid form. The fermentation broth or broth concentrate can be dried with or without the incorporation of vehicles by using conventional drying methods or processes such as spray drying, freeze-drying, tray drying, fluidized bed drying, drum drying, or evaporation. The resulting dried products can undergo further processing, such as milling or granulation, to achieve a specific particle size or physical form. Carriers, described below, can also be added after drying. The expression “fermentation product” as used herein refers to fermentation broth, broth concentrate and / or dry fermentation broth or broth concentrate, which is referred to herein as dry fermentation broth. Cell-free preparations of fermentation broth from the strains of the present invention can be obtained by any means known in the art, such as extraction, centrifugation, and / or filtration of the fermentation broth. Those skilled in the art will appreciate that so-called cell-free preparations may not be entirely cell-free but rather largely or essentially cell-free, depending on the technique used (e.g., centrifugation speed) to remove the cells. The resulting cell-free preparation can be dried and / or formulated with components that will aid in its application to plants or plant growth media. The concentration methods and drying techniques described above for fermentation broth can also be applied to cell-free preparations. In one embodiment, the fermentation product comprises at least approximately 1 × 10⁵ colony-forming units (CFU) of the microorganism (e.g., Bacillus spp. NRRL B-67746, or a plant health-enhancing or plant growth-promoting strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least approximately 1 × 10⁶ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting strain thereof) / mL of broth. In yet another embodiment, the fermentation product comprises at least approximately 1 × 10⁷ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least approximately 1 x 10⁸ CFU of the microorganism (e.g., Bacillus spp.In another embodiment, the fermentation product comprises at least approximately 1 x 10⁹ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least approximately 1 x 10¹⁰ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant growth-promoting strain thereof) / mL of broth. In another embodiment, the fermentation product comprises at least approximately 1 x 1011 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a strain of the plant growth-promoting mutant thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry broth comprising at least approximately 1 × 10⁸ colony-forming units (CFU) of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least approximately 1 × 10⁹ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least approximately 1 × 1010 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a strain of the plant health-enhancing mutant thereof) / mL of broth.In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least approximately 1 × 10¹¹ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least approximately 1 × 10¹² CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a plant health-enhancing mutant strain thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least approximately 1 × 1013 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a strain of the plant health-enhancing mutant thereof) / mL of broth.In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising at least approximately 1 x 10¹⁴ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a strain of the plant health-enhancing mutant thereof) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising approximately 1 x 10⁸ CFU to approximately 1 x 10¹⁴ CFU. CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a strain of the plant health-enhancing mutan) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising approximately 1 x 10⁹ CFU to approximately 1 x 10¹³ CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a strain of the plant health-enhancing mutan) / mL of broth. In another embodiment, the fermentation product is a broth concentrate or a dry fermentation broth comprising approximately 1 x 1010 CFU to approximately 1 x 1012 CFU of the microorganism (e.g., Bacillus spp. NRRL B-67746 or a strain of the plant health-enhancing mutan thereof) / mL of broth. In another embodiment, the fermentation product comprises approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 15%, approximately 20%, or approximately 25% fermentation solids. The fermentation solids include spores, vegetative cells, and unused fermentation media. In certain aspects, the fermentation product comprises approximately 1% to approximately 60% fermentation solids, e.g. e.g., any range within 1% to 60%, such as 1% to 50%, 1% to 40%, 1% to 30%, 1% to 25%, 1% to 20%, 1% to 15%, 1% to 10%, 30% to 60%, 40% to 60%, etc.In certain aspects, the fermentation product comprises approximately 1% to approximately 25% fermentation solids, approximately 1% to approximately 20% fermentation solids, approximately 1% to approximately 15% fermentation solids, or approximately 1% to approximately 10% fermentation solids. The compositions of the invention can be used as such or, according to their particular physical and / or chemical properties, in the form of their formulations or use forms prepared from them, such as aerosols, capsule suspensions, cold spray concentrates, hot spray concentrates, encapsulated granules, fine granules, seed treatment flow concentrates, ready-to-use solutions, dustable powders, emulsifying concentrates, oil-in-water emulsions, water-in-oil emulsions, macrogranules, microgranules, oil-dispersible powders, oil-miscible flow concentrates, oil-miscible liquids, gas (under pressure), gas-generating product, foams, pastes, pesticide-coated seeds, suspension concentrates, oil dispersion, suspoemulsion concentrates, soluble concentrates, suspensions, including encapsulated suspensions where, for example,An oily dispersion containing solid particles encapsulated in water, wettable powders, soluble powders, powders and granules, water-dispersible and water-soluble granules or tablets, water-dispersible and water-soluble powders for seed treatment, wettable powders, natural products and synthetic substances impregnated with an active ingredient, microdispersions and also microencapsulations in polymeric substances and in seed coating materials, and also ULV cold-spray and hot-spray formulations. In one aspect, the biologically pure cultures or related fermentation products of the present invention are combined with a carrier suitable for agriculture. Such carriers suitable for agriculture may be the formulation inerts described below. In one particular aspect, the compositions of the present invention are formulated for the treatment of seeds as dry dustable powders, fluid suspensions or suspension concentrates, liquid solutions, water-soluble powders or water-dispersible powders. In some embodiments, the compositions of the invention are liquid formulations. Non-limiting examples of liquid formulations include oily suspension and dispersion concentrates. In other embodiments, the compositions of the invention are solid formulations. Non-limiting examples of liquid formulations include freeze-dried powders and spray-dried powders. The compositions of the present invention may include formulation inerts added to compositions comprising cells, cell-free preparations, and / or metabolites to improve efficacy, stability, and utility, and / or to facilitate processing, packaging, and end-use application in agriculture. Such formulation inerts and ingredients may include carriers, stabilizing agents, nutrients, or physical property modifiers, which may be added individually or in combination. In some embodiments, the carriers may include liquid materials such as water, oil, and other organic or inorganic solvents, and solid materials such as minerals, polymers, or polymer complexes of biological origin or obtained by chemical synthesis. In some embodiments, the carrier is a fixative or adhesive that facilitates the adhesion of the composition to a part of the plant, such as a seed or root.See, for example, Taylor, AG, et al., “Mandas and Technologies of Selected Seed Treatments,” Annu. Rev. Phytopathol. 28: 321-339 (1990). Stabilizing agents may include anticaking agents, antioxidants, desiccants, protectants, or preservatives. Nutrients may include sources of carbon, nitrogen, or phosphorus such as sugars, polysaccharides, oils, proteins, amino acids, fatty acids, and phosphates, or micronutrients such as manganese. Physical property modifiers may include binding agents, wetting agents, thickeners, pH modifiers, rheological property modifiers, dispersants, adjuvants, surfactants, antifreeze agents, or colorants. In some embodiments, the composition comprising cells, cell-free preparations, or fermentation-produced metabolites may be used directly with or without water as a diluent, without further formulation preparation.In some embodiments, the formulation inerts are added after concentrating the fermentation broth and during and / or after drying. In certain aspects, the fermentation product also comprises a formulation ingredient. The formulation ingredient may be a wetting agent, a diluent, a solvent, a growth promoter, an emulsifier, a dispersant, a frost protectant, a thickener, and / or an adjuvant. In one embodiment, the formulation ingredient is a wetting agent. The compositions of the present invention may include the addition of formulation ingredients to improve recovery, efficacy, or physical properties and / or to aid in processing, packaging, and administration. Such formulation ingredients may be added individually or in combination. Formulation ingredients may be added to compositions comprising cells, cell-free preparations, and / or metabolites to enhance efficacy, stability, physical properties, usability, and / or to facilitate processing, packaging, and end-use application. Such formulation ingredients may include carriers, inert materials, stabilizing agents, preservatives, nutrients, or physical property modifiers, which may be added individually or in combination. In some embodiments, carriers may include liquid materials such as water, oil, and other organic or inorganic solvents, and solid materials such as minerals, polymers, or polymer complexes of biological origin or obtained by chemical synthesis.In some embodiments, the formulation ingredient is a fixative, adjuvant, or adhesive that facilitates the adhesion of the composition to a part of the plant, such as the leaves, seeds, or roots. See, for example, Taylor, AG, et al., “Concepts and Technologies of Selected Seed Treatments,” Annu. Rev. PhytopathoL, 28: 321-339 (1990). Stabilizing agents may include anticaking agents, antioxidants, antisedimentation agents, antifoaming agents, desiccants, protectants, or preservatives. Nutrients may include sources of carbon, nitrogen, or phosphorus such as sugars, polysaccharides, oils, proteins, amino acids, fatty acids, phosphates, macronutrients, and micronutrients. Macronutrients include nitrogen, phosphorus, potassium, calcium, sulfur, and magnesium. Micronutrients include zinc, boron, manganese, iron, copper, sodium, molybdenum and nickel, generally in trace amounts.Physical property modifiers may include binding agents, wetting agents, thickeners, pH modifiers, rheological property modifiers, dispersants, adjuvants, surfactants, film formers, hydrotropic agents, sequestering agents, antifreeze agents, or colorants. In some embodiments, the composition comprising cells, cell-free preparations, and / or fermentation-produced metabolites may be used directly with or without water as a diluent, without further formulation preparation. In one particular embodiment, a wetting agent or a dispersant is added to a dry broth concentrate, such as a freeze-dried or spray-dried powder. A wetting agent enhances dispersion and penetration properties; a dispersant enhances the dispersibility and solubility of the active ingredient (once diluted) when applied to surfaces.Examples of wetting agents are known to those skilled in the art and include sulfosuccinates and derivatives such as MULTIWET™ MO-70R (Croda Inc., Edison, NJ); siloxanes such as BREAK-THRU® (Evonik, Germany); nonionic compounds such as ATLOX™ 4894 (Croda Inc., Edison, NJ); alkyl polyglucosides such as TERWET® 3001 (Huntsman International LLC, The Woodlands, Texas); C12-C14 alcohol ethoxylates such as TERGITOL® 15-S-15 (The Dow Chemical Company, Midland, Michigan); phosphate esters such as RHODAFAC® BG-510 (Rhodia, Inc.); and alkyl ether carboxylates such as EMULSOGEN™ LS (Clariant Corporation, North Carolina). The present invention provides combinations of compounds comprising (a) the Bacillus spp. strain.NRRL B-67746 or a plant growth-promoting mutant of this strain and (b) at least one additional active compound against at least one plant pathogen and / or plant pest or active in promoting plant growth, including fungicides, insecticides, nematicides and microbe-based products. Chemical fungicide mixing partner (b) In one embodiment, the active compound combinations according to the invention comprise, as compound (b), at least one additional active compound selected from the following groups: (1) ergosterol synthesis inhibitors, (2) respiratory chain inhibitors at complex I or II, (3) respiratory chain inhibitors at complex III, (4) inhibitors of mitosis and cell division, (5) compounds capable of having multisite action, (6) compounds capable of inducing host defense, (7) inhibitors of amino acid and / or protein biosynthesis, (8) inhibitors of ATP production, (9) inhibitors of cell wall synthesis, (10) inhibitors of lipid and membrane synthesis, (11) inhibitors of melanin biosynthesis, (12) inhibitors of nucleic acid synthesis, (13) inhibitors of signal transduction, (14) compounds capable of functioning as decouplers,(15) other fungicides selected from the group consisting of (15.001) abscisic acid, (15.002) benthiazole, (15.003) betoxazine, (15.004) capsicin, (15.005) carvone, (15.006) quinomethionate, (15.007) cufraneb, (15.008) cyflufenamide, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) flutianil, (15.012) fosetyl-aluminum, (15.013) fosetyl-calcium, (15.014) fosetylsodium, (15.015) methyl isothiocyanate, (15.016) metrafenone, (15.017) mildiomycin, (15.018) natamycin, (15.019) nickel dimethyldithiocarbamate, (15.020) nitrothal-isopropyl, (15.021) oxamocarb, (15.022) oxathiapiproline, (15.023) oxyphenthiine, (15.024) pentachlorophenol and salts, (15.025) phosphonic acid and its salts, (15.026) propamocarb-fosetylate, (15.027) pyriophenone (clazafenone), (15.028) tebufloquine, (15.029) teclophthalam, (15.030) tolnifanide, (15.031) 1 -(4-{4[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1 -yl)-2-[5-methyl-3- (trifIuorometiI)-1 H-pyrazol-1 -yl]ethanone,(15.032) 1 -(4-{4-[(5S)-5-(2,6-difluorophene¡I)-4,5-dihydro-1,2oxazol-3-¡ l]-1,3-thiazol-2-yl}piperidin-1 -yl)-2-[5-methyl-3-(tr¡fluoromethyl-pyrazol-1)-1 -yl]ethanone, (15,033) 2-(6-benzylp¡r¡n-2-¡l)quinazoline, (15,034) dipimetritone, (15,035) 2-[3,5bis(difluoromet¡l)-1 H-pyrazol-1 -yl -[4-(4-{5-[2-(prop-2-in-1 -yloxy)phen¡l]-4,5-d¡hydro-1,2-oxazol-3-yl}1,3-thiazol-2-yl)p¡peñd¡n-1 -yl]ethanone, (15.036) 2-[3,5-difluoromethane-1) H-pyrazol-1-yl]-1-[4-(4-{5-[2chloro-6-(prop-2-in-1 -yloxy)phen¡l]-4,5-d¡hydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1 -yl]ethanone, (15.03) 2-[3,5-bis(difluoromethyI)-1 H-pyrazol-1 -yl]-1 -[4-(4-{5-[2-fluoro-6-(prop-2-in-1 -yloxy)phenyl]-4,5dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-pyridine-1,1] (15,038) 2-[6-(3-fluoro-4-methoxyphenyl)5-methylp¡r¡d¡n-2-¡l]quinazoline, (15,039) 2-{(5R)-3-[2-(1 -{[3,5-bis(difluoromethyl)-1-pyrazol-1 yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-d¡h¡dro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate,(15.040) 2-{(5S)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]q izmin / zz / E / yLi, 4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (15.041) 2-{2-[(7,8-difluoro-2methylquol¡na-3-¡l)ox¡]-6-fluorophen¡l}propane-2-2,0.041) 2-{2-fluoro-6-[(8-fluoro-2-methylquinol¡na3-¡l)oxy]phenyl}propan-2-ol, (15,043) fluoxapiproline, (15,044) 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1 Hopyrazole-1 -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phen¡ I methanesulfonate, (15,045) 2-phenylphenol and its salts, (15,046) 3-(4,4,5-trifluoro-3,3-d¡meth¡l-3,4-d¡h¡droisoquinolin-1 yl)quinoline, (15,047) quinophemline, (15,048) 4-amino-5-fluoropyrimidin-2-ol (tautomeric form: 4-amino-pyrino-2-chromodinone), (2-1) (15,049) 4-oxo-4-[(2-phenylethyl)am¡no]butano¡co acid, (15,050) 5-amino-1,3,4-thiadiazol-2-thiol, (15,051) 5-chloro-N'-phenyl-N'-(prop-2-in-1-hydrylphino-sulphino-2), (15,050) (15,052) 5-fluoro-2-[(4-fluorobenzyl)ox¡]p¡r¡m¡d¡n-4-am¡na, (15,053) 5-fluoro-2-[(4methylben¡l)ox¡]p¡r¡m¡m¡m¡n-4, (15.5.054) 9-f luoro-2,2-d¡ methyl-5-(quinolin-3-¡ I )-2,3-dih hydro-1,4benzoxazepine, (15,055) but-3-in-1-yl {6-[({[(Z)-(1-met¡l-1H-tetrazol-5¡l)(phenyl)meth¡len]am¡no}ox¡)meth¡l]p¡r¡d¡n-2-¡l}carbamate, (15.056) ethyl (2Z)-3-amino-2-phenylacrylate (5.5.5). phenazine-1-carboxylic acid, (15,058) propyl 3,4,5-trihydroxybenzoate, (15,059) quinolin-8-ol, (15,060) quinolin-8-ol sulfate (2:1), (15,061) tert-butyl {6-[({[(1-methyl-1H-tetrazol-5¡l)(phenyl)meth¡len]am¡no}ox¡)meth¡l]p¡r¡d¡n-2-¡l}carbamate, (15,062) 5-fluoro-4-imino-3-met¡l-1 -[(4methylphenyl)sulfonyl]-3,4-dihydropyr¡m¡d¡n-2(1 H)-one, (15,063) aminopyrifhene, (15,064) (N'-[2-chloro-4(2-fluorophenoxy)-5-meth¡lphen¡l]-N-et¡lN-met¡l¡l¡mdoformamide), (15.065) (N'-(2-chloro-5-methyl-4phenoxyphenyl)-N-et¡lN-meth¡l¡mdoformamide (15.6), (2-{2-[(7,8-difluoro-2-methylquinoline-3-yl)oxy]-6fluorophenyl}propan-2-ol), (15,067) (5-bromo-1 -(5,6-dimethylpyridi η-3-i I )-3,3-dimethyl-3,4dihydroisoquinoline), (15.067).068) (3-(4,4-difluoro-5,5-dimetil-4,5-dihidrotieno[2,3-c]piridin-7il)qu ¡noli na), (15.069) (1 -(4,5-dimeti 1-1 H-benczimidazol-1 -i l)-4,4-dif luoro-3,3-d¡ metil-3,4dihidroisoquinolina), (15.070) 8-fluoro-3-(5-fluoro-3,3-d¡metil-3,4-dihidroisoquinolin-1 -il)qu¡nolona, (15.071) 8-fluoro-3-(5-fluoro-3,3,4,4-tetrametil-3,4-d¡hidroisoqu¡nol¡n-1 -il)quinolona, (15.072) 3(4,4-difluoro-3,3-dimetil-3,4-dih¡droisoquinolin-1 -il)-8-fluoroquinolina, (15.073) (N-metil-N-fenil-4[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida), (15.074) metil {4-[5-(trifluorometil)-1,2,4oxadiazol-3-il]fenil}carbamato, (15.075) (N-{4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]bencil}c¡clopropanocarboxamida), (15.076) N-metí l-4-(5-(trifl uorometi l)-1,2,4-oxadiazol-3il]benzamida, (15.077) N-[(E)-metoxi¡minometil]-4-[5-(tr¡fluoromet¡l)-1,2,4-oxadiazol-3il]benzamida, (15.078) N-[(Z)-metoxi¡minometil]-4-[5-(tr¡fluoromet¡l)-1,2,4-oxadiazol-3il]benzamida, (15.079) N-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-¡l]phenyl]cyclopropanocarboxam¡da, (15,080) N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-miylbenzal-3-¡1,108. 2,2difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phen¡l]acetam¡da, (15,082) N-allylo-N-[[4[5-(trifluorometh¡l)-1,2,4-oxad¡azol-3-yl)phen¡l]meth¡l]acetamide, (15,083) N-[(E)-N-methoxy-C-methylq Lznnn / zznz / E / YiAi carbon-(4-trif-(4-) luoromethyl)-1,2,4-oxadiazol-3-yl]benzamide, (15,084) N-[(Z)-N-methoxy-Cmet¡l-carbon¡m¡do¡l]-4-[5-(tr¡fluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (15,584). In N-allylo-N-[[4-[5(trifluoromethy l)-1,2,4-oxadiazol-3-yl]phenyl]met¡l]propanam¡da, (15,086) 4,4-dimethyl-1 -[[4-[5(trifIuoromethyI)-1,2,4-oxadiazol-3-yl]phenyl]meth¡l]p¡rrolid¡n-2-one, (15,087) N-methyl-4-[5-(trifluoromethyl)1,2,4-oxadiazol-3-yl]bencenocarbon (8¡8,15.8). 5-methyl-1 -[[4-[5-(trif luoromethyl)-1,2,4oxadiazol-3-¡l]phen¡l]met¡l]p¡rrolid¡n-2-one, (15.089) N-((2,3-difluoro-4-[5-(tr¡fluorometil)-1,2,4oxadiazol-3-¡l]fen¡l]metil]-3,3,3-tr¡fluoro-propanam¡da, (15.090) 1 -methoxy-1 -metil-3-[[4-[5(trifluorometil}-1,2,4-oxadiazol-3-yl]fen¡l]met¡l]urea, (15.091) 1,1 -diethyl-3-[[4-[5-(trifluorometil}-1,2,4oxadiazol-3-yl]fen¡l]metil]urea, (15.092) N-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3yl]fenil]metil]propanam¡da, (15.093) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, (15.094) 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl]methyl]urea, (15.095) N-methoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl)cyclopropanecarboxamide, (15.096) N,2-dimethoxy-N-[[4-[5-(trifluoromethyl}-1,2,4oxadiazol-3-yl]phenyl]methyl]propanamide, (15.097) N-etil-2-metil-N-[[4-[5-(tr¡fluoromet¡l)-1,2,4oxadiazol-3-yl)phen¡l]met¡l]propanam¡da, (15.098) 1 -methoxy-3-metil-1 -[[4-[5-(trifluorometil)-1,2,4oxadiazol-3-yl]fen¡l]met¡l]urea, (15.099) 1,3-dimethoxy¡-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3yl]f enyl]meth¡ l]u rea, (15.100) 3-ethyl 1-1 -methox¡-1 -[[4-[5-(trifl uoromethyl) l)-1,2,4-oxadiazol-3yl]phenyl]meth¡l]urea, (15.101) 1 -[[4-[5-(trifluoromethyl)-1,2,4-oxad¡azol-3-¡l]phenyl]meth¡l]p¡per¡d¡n-2-one, (15.10.5) 4,4-dimethyl-2-[[4-[5-(tr¡fluorometh¡l)-1,2,4-oxadiazol-3-¡l]phen¡l]meth¡l]¡sooxazolid¡n-3-one, (15.103) 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-¡l]phen¡l]met¡l]¡soxazolid¡n-3-one, (15,104) 3,3-dimethyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-¡l]phen¡l]met¡l]p¡perid¡n-2-one, (15.105) 1-[[3-fluoro-4-(5-(tr¡fluoromet¡l)-1,2,4-oxad¡azol-3-yl]phen¡l]methyl]azepan-2-one, (15.106) 4,4-dimethyl2-[[4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-¡l]phen¡l]met¡l]¡soxazolid¡n-3-one, (15.107) 5,5-dimethyl-2-[[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phen¡l]meth¡l]¡soxazol¡d¡n-3-one, (15.108) ethyl 1 -{4-[5(trifluoromethyl)-1,2,4-oxylzol-3-cl}] H-pyrazole-4-carboxylate, (15109) N,N-dimethyl-1 -{4-[5(trifluoromethyl)-l ,2,4-oxadiazol-3-yl]benc¡l}-1 H-1,2,4-triazol-3-amine, (15.110) N-{2,3-difluoro-4-[5(trifl I) -1,2,4-oxadiazol-3-yl]benc¡l}butan¡da, (15.111) N-(1 -methylc¡chlopropyl)-4-[5- (trifluoromethyI)-1,2,4-oxadiazol-3-yl]benzam¡da, (15.112) N-(2,4-difluorophenyl)-4-[5-(trifluoromethyΟΙ ,2,4-oxadiazol-3-yl]benzamide, (15,113) 1 -(5,6-d¡ methi lpyri¡din-3-¡l)-4,4-d¡f chloro-3,3-methylhydroline,3,4 (15.114) 1 -(6-(difluoromethyl)-5-meth¡lp¡r¡din-3-¡l)-4,4-d¡fluoro-3,3-d¡methyl-3,4dihydroisoquinoline, (15,115) 1 -(5-(fl uoromethyl)-6-pyrimethyl n-3-yl)-4,4-dif luoro-3,3-dimet¡ I-3,4dihydroisoquinoline, (15.116) 1 -(6-(difluoromethyl)-5-methoxy¡-pyridin-3-yl)-4,4-d¡fluoro-3,3-dimethyl-3,4-isoquinoline (15.17). 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phen¡l dimethylcarbamate, (15.118) Ν-{4-[5-(trifluoromethyI)-1,2,4-oxadiazol-3-yl]phen¡l}propanam¡da, (15.118).119) 3-[2-(1 -{[5-methyl3-(trifluoromethyl)-1 H-pyrazol-1 -yl]acet¡ l}piperid¡n-4-¡l)-1,3-thiazol-4-yl]-1,5-dihydro-2,4-benzod¡oxep¡n6-yl methanol, 12,10. 9-fluoro-3-[2-(1-{[5-methyl-3-(trifluorometh¡l)-1 H-pyrazol-1 yl]acetyl}p¡peridin-4-yl)-1,3-1¡azol-4-yl]-1,5-dihydro-2,4-benzod¡oxep¡n-methanol (2,1,15). 3-(2-(1 -{[3,5-bis(difluoromethyl)-1 H-pyrazol-1 -yl]acetyl}p¡per¡di η-4-yl)-1,3-thiazol-4-¡ I]-1,5-d¡ hydro-2,4benzodioxepin-6-yl methanosulfonate, (1)(2-1(2)-15. -{[3,5-bis(difluoromet¡l)-1 H-pyrazol-1 - yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-9-fluoro-1,5-dihydro-2,4-benzod¡oxep¡n-6-¡l methanosulfonate, (13) -(6,7-dimethylp¡razolo[1,5-a]pi ridi n-3-yl)-4,4-d if I uoro-3,3-di methi l-3,4-dih hydroisoqu ¡noli na, (15,124) 8-fluoro-N-(4,4,4-trifluoro-2-met¡l-1-phen¡lbutane-2-¡l)qu¡noline-3-carboxam¡da, (15,125) 8fluoro-N-[(2S)-4,4,4-trifluoro-2-met¡l-1 -phenylbutan-2-¡l]qu¡noline-3-carboxam¡da, (15.126) N-(2,4dimethyl-1-phenylpentan-2-l)-8-fluoroqu¡noline-3-carboxam¡da and (15.127) N-[(2S)-2,4-dimethyl-1phenylpentan-2-¡l]-8-fluoroquinol¡na-3-carboxam¡da. The item (B) is preferably selected from: inhibidores de la síntesis de ergosterol seleccionados del grupo que consiste en (1.001) ciproconazol, (1.002) difenoconazol, (1.003) epoxiconazol, (1.004) fenhexamida, (1.005) fenpropidina, (1.006) fenpropimorf, (1.007) fenpirazamina, (1.008) fluquinconazol, (1.009) flutriafol, (1.010) imazalilo, (1.011) sulfato de imazalilo, (1.012) ipconazol, (1.013) metconazol, (1.014) miclobutanilo, (1.015) paclobutrazol, (1.016) procloraz, (1.017) propiconazol, (1.018) protioconazol, (1.019) pirisoxazol, (1.020) espiroxamina, (1.021) tebuconazol, (1.022) tetraconazol, (1.023) triadimenol, (1.024) tridemorf, (1.025) triticonazol, (1.026) (1R,2S,5S)-5-(4clorobencil)-2-(clorometil)-2-met¡l-1 -(1H-1,2,4-triazol-1 -iimetíl)ciclopentanol, (1.027) (1 S,2R,5R)-5(4-clorobencil)-2-(clorometil)-2-met¡l-1 -(1 H-1,2,4-triazol-1 -ilmetil)c¡clopentanol, (1.028) (2R)-2-( 1 clorociclopropil)-4-[( 1 R)-2,2-diclorocicloprop¡l]-1 -(1 H-1,2,4-triazol-1 -il)butan-2-ol, (1.029) (2R)-2(1 -chlorocyclopropyl)-4-[(1 S)-2,2-dichlorocycloprop¡l]-1 -(1 H-1,2,4-triazol-1 -yl)butan-2-ol, (1.030) (2R)2-[4-(4-chlorophenoxy)-2-(trifluoromet¡l)phen¡l]-1 -(1 H-1,2,4-triazol-1 -yl)propan-2-ol, (1.031) (2S)-2-(1 chlorocyclopropyl)-4-[( 1 R)-2-( H-1,2,4-triazol-1 -yl)butan-2-ol, (1.032) (2S)-2(1 -chlorocyclopropyl)-4-[(1 S)-2,2-dichlorocyclopropyl]-1 -(1 H-1,2,4-triazol-1 -yl)butan-2-ol, (1.033) (2S)2-[4-(4-chlorophenox¡)-2-(tnfluoromet¡l)phenyl]-1 -(1 H-1,2,4-tr¡azol-1 -yl)propan-2-ol, (1.034) (R)-[3-(4chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-¡l](p¡ridin-3-¡l)methanol, (1.035) (S)-[3-(4-chloro2-fluorophenyl)-5-dif(2,4-f luorophenyl)-1,2-oxazol-4-yl](pyrid¡n-3-¡ l)methanol, (1.036) [3-(4-chloro-2fluorophenyl)-5-(2,4-difluorophen¡l)-1,2-oxazol-4-yl](p¡dyn-3-l-4-yl)(1.07). -({(2R,4S)-2-[2-chloro4-(4-chlorophenoxy)phen¡l]-4-methyl-1,3-d ¡oxolan-2-yl}methyl)-1 H-1,2,4-triazole, (1.038) 1 -({(2S,4S)-2-[2chloro-4-(4-chlorophenoxy)phen¡l]-4-meth¡l-1,3-dioxolan-2-yl}methyl)-1 H-1,2,4-triazole, (1.039) 1 -{[3-(2q L / l chlorophenyl)-2-(2,4-difluorophen¡ l)oxiran-2-yl]meth¡l}-1 H-1,2,4-triazol-5-yl thiocyanate, (1,040) 1 {[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-d¡fluorophen¡l)ox¡ran-2-¡l]meth¡l}-1 H-1,2,4-triazol-5-yl thiocyanate, (1,041) 1 -{[reí (2R,3S)-3-(2-chlorophenyl)-2-(2,4-dif luorophenyl)oxiran-2-yl]met¡ l}-1 H-1,2,4-triazole-5-¡ I thiocyanate, (1,042) 2-[(2R,4R,5R)-1 -(2,4-dichlorophene yl)-5-hydroxy-2,6,6-tri methiptan-4-yl]-2,4dihydro-3H-1,2,4-triazole-3-thione, (1,043) 2-[(2R,4R,5S)-1-(2,4-dichlorophenyl)-5-h¡drox¡-2,6,6trimethylheptane-4-¡l]-2,4-d¡h¡dro-3H-1,2,4-triazol-3-thione, (1,044) 2-R,4-(2,5S)-R -(2,4-dichlorophenyl)5-h¡drox¡-2,6,6-tr¡meth¡lheptan-4-yl]-2,4-d¡hydro-3H-1,2,4-triazol-3-thione, (1.045) 2-[(2R,4S,5S)-1(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (1046) 2[(2S,4R,5R)-1-(2,4-d¡chlorophen¡l)-5-h¡drox¡-2,6,6-tr¡methylheptane-4-¡l]-2,4-d¡h¡dro-3H-1,2,4-triazole-304, (1.7) 2-[(2S,4R,5S)-1 -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptane-4-¡l]-2,4-dihydro-3H1,2,4-triazole-3-thione, (1.048) 2-[(2S,4,4R)-1 -(2,4-dichlorophen¡l)-5-hydroxy-2,6,6-tr¡methylheptan-4-yl]2,4-dihydro-3H-1,2,4-triazol-3-thione, (1.049) 2-[(2S,4S,5S)-1-(2,4-dichlorophenyl)-5-h¡drox¡-2,6,6tri methyl I heptane-4-¡l]-2,4-dih hydro-3 H -1,2,4-triazol-3-thiona, (1,050) 2-[1 -(2,4-dichlorophenyl)-5-h¡drox¡2,6,6-trimethylheptan-4-yl]-2,4-d¡ hydro-3H-1,2,4-triazol-3-thione, (1,051) 2-[2-chloro-4-(2,4dichlorophenol-1-1-1) H-1,2,4-triazol-1-yl)propan-2-ol, (1.052) 2-[2-chloro-4-(4-chlorophenoxy)phen¡l]-1(1 H-1,2,4-triazol-1 -yl)butan-2-ol, (1.053) 2-[4-(4-chlorophenoxy)-2-(tr¡fluoromet¡l)phen¡l]-1 -(1 H-1,2,4triazol-1 -yl)butan-2-ol, (1.054) 2-[4-(4-chlorophenoxy)-2-(tr¡fluorometh¡l-1-1) H-1,2,4-triazole-1 yl)pentane-2-ol, (1.055) mefentrifluconazole, (1.056) 2-{[3-(2-chlorophenyl)-2-(2,4-difluorophen¡l)ox¡ran-2yl]methyl}-2,4-d¡ hydro-3H-1,2,4-triazole-3-thione, (1.057) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4difluorophen¡l)ox¡ran-2-¡l]met¡l}-2,4-d¡hydro-3H-1,2,4-triazol-3-thione, (1,058) 2-{[rel(2R,3S)-3-(2chlorophenyl)-2-(2,4-d¡fluorophen¡l)oxiran-2-¡l]methyl}-2,4-d¡h¡dro-3H-1,2,4-triazol-3-thione, (1.059) 5-(4chlorobenzyl)-2-(chloromet¡l)-2-met¡l-1 -(1 H-1,2,4-triazol-1 -ylmethyl)cyclopentanol, (1.060) 5-(al¡ Issue I)1 -{[3-(2-chlorophenyl)-2-(2,4-difIuorophenyl)oxiran-2-yl]met¡I}-1 H-1,2,4-triazole, (1.061) 5-(allylsulfanyl)-1 {[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-d¡fluorophen¡l)oxiran-2-¡ l]methyl}-1 H-1,2,4-triazole, (1.062) 5(allylsulfan¡l)-1 -{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-d¡fluorophen¡l)ox¡ran-2-¡l]meth¡l}-1 H-1,2,4-triazole, (1.063) N'-(2,5-dimethyl-4-{[3-(1,1,2,2-tetrafluoroethoxy)phenyl]sulfan¡l}phen¡l)-N-et¡l-Nmethylimidoformamide, (1.064) N'-(2,5-dimeth¡l-4-{[3-(2,2,2-tr¡fluoroethoxy¡)phen¡l]sulfan¡l}phen¡l)-N-et¡l-Nmethylimidoformamide, (1.065) N'-(2,5-dimeth¡l-4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl}phenyl)-Nethyl-N-methylimidoformamide, (1.066) N'-(2,5-d¡met¡l-4-{[3-(pentafluoroethoxy)phen¡l]sulfan¡l}phen¡l)-Nethyl-N-methylimidoformamide, (1.067) N'-(2,5-dimethyl-4-{3-[(1,1,2,2tetrafluoroet¡l)sulfan¡l]phenox¡}phen¡l)-N-et¡lN-met¡l¡midoformam¡da, (1.068) N'-(2,5-dimethyl-4-{3[(2,2,2-tr¡fluoroet¡l)sulfan¡l]phenoxy¡}phenyl)-N-et¡lN-met¡l¡m¡m¡doformam¡da, (1.069) N'-(2,5-dimethyl-4-{3[(2,2,3,3-tetrafluoroprop¡l)sulfan¡l]phenox¡}phen¡l)-N-et¡lN-meth¡l¡midoformamide, (1.070) N'-(2,520 dimethyl l-4-{3-{3-penta) yl]phenoxy}ph enyl)-N-et¡ lN-methyl imidof ormam ¡da, (1.071) N'-(2,5d¡methyl-4-phenoxyphen¡l)-N-ethyl-N-methylim¡doformamide, (1.072) N'-(4-{[3-(difluoromethoxy)phenyl]sulfanyl}2,5-dimeth¡lphenyl)-N-ethyl-N-methyl¡m¡doformam¡da, (1.073) N'-(4-{3-[(difluoromethyl)sulfanyl]phenoxy}-2,5d¡methylphen¡l)-N-et¡lN-met¡l¡midoformam¡da, (1.074) N'-[5-bromo-6-(2,3-dihydro-1 H-inden-2-ilox¡)-2met¡lpyridin-3-yl]-N-et¡lN-methyl¡midoformam¡da, (1.075) N'-{4-[(4,5-d¡chloro-1,3-thiazol-2-yl)ox¡]-2,5dimeth¡lphen¡l}-N-et¡lN-methylim¡doformam¡da, (1.076) N'-{5-bromo-6-[(1 R)-1-(3,5-difluorophenyl)ethoxy]2-met¡lp¡r¡d¡n-3-¡l}-N-ethyl-N-methyl¡mdoformamide, (1.077) N'-{5-bromo-6-[(1S)-1-(3,5d¡fluorophen¡l)ethoxy]-2-methylpyr¡d¡n-3-¡l}-N-et¡lN-methylim¡doformam¡da, (1.078) N'-{5-bromo-6-[(cis-4¡sopropylcyclohex¡l)ox¡]-2-methylpyr¡din-3-¡l}-N-et¡lN-methylim¡doformam¡da, (1.079) N'-{5-bromo-6[(trans-4-¡soprop¡lcyclohex¡l)ox¡]-2-met¡lp¡r¡n-3-¡l}-N-et¡lN-meth¡lim¡doformam¡da, (1,080) N'-{5-bromo-6-[1. -(3,5-d¡fluorophen¡l)ethox¡]-2-met¡lp¡r¡d¡n-3-yl}-N-ethyl-N-met¡l¡mdoformamide, (1.081) ipfentrifluconazole, (1.082) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1 -(1H-1,2,4-triazol-1 yl)propan-2-ol, (1.083) 2-[6-(4-bromophenoxy)-2-(tr¡fluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan2-ol, (1.084) 2-[6-(4-chlorophenoxy)-2-(tr¡fluoromethyl)-3-pyridyl]-1 -(1,2,4-triazol-1 -yl)propan-2-ol, (1.085) 3-[2-(1 -chlorocycloprop¡l)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-prop¡l]¡m¡dazol-4-carbon¡tr¡lo, (1.086) 4[[6-[rac-(2R)-2-(2,4-difluorophenyl)-1,1 -difluoro-2-hydrox¡-3-(5-t¡oxo-4H-1,2,4-tr¡azol-1 -yl)prop¡ l]-3pyridyl]oxy]benzonitrile, (1,087) N-isopropyl-N'-[5-methoxy-2-met¡l-4-fluoro-2,2,2 -hydroxy-1 phenyleth¡l)phen¡l]-N-meth¡l¡m¡doformamide, (1.088) N'-{5-bromo-2-methyl-6-[(1-propoxypropane-2¡l)oxy]pyridin-3-yl}-N-et¡lN-methylimidoformate, hexaconazol (1.089) (1.090) penconazole and (1.091) fenbuconazole;. respiratory chain inhibitors in complex I or II selected from the group consisting of (2001) benzovindiflupir, (2002) bixaphene, (2003) boscalid, (2004) carboxin, (2005) fluopyram, (2006) flutolanil, (2007) fluxapiroxad, (2008) furametpir, (2009) isofetamide, (2010) isopyrazam (antiepimeric enantiomer 1R, 4S, 9S), (2011) isopyrazam (antiepimeric enantiomer 1S,4R,9R), (2012) isopyrazam (antipimeric enantiomer 1S,4R,9R), (2013) isopyrazam (mixture of sinepimeric recemate 1 RS,4SR,9RS and antiepimeric acemate 1 RS,4SR,9SR), (2014) isopyrazam (synepimeric enantiomer 1R,4S,9R), (2015) isopyrazam (synepimeric enantiomer 1R,4S,9R), (2016) isopyrazam (sinepimeric recemate 1 RS,4SR,9RS), (2017) penflufen, (2018) pentiopyrate, (2019) pidiflumetophen, (2020) pyraziflumide, (2021) sedaxane, (2022) 1,3-trimethyl, 1,3-N l-2,3-dihydro-1 H-inden-4-yl)-1 H-pyrazol-4-carboxamide, (2023) 1,3-dimethyl-N-[(3R)1,1,3-trimethy l-2,3-dihydro-1 H-inden-4-yl]-1 H-pyrazol-4-carboxamide,(2024) 1,3-dimethyl-N-[(3S)1,1,3-trimetil-2,3-dihydro-1H-inden-4-il]-1H-pirazol-4-carboxamide, (2025) 1-methyl-3-(trifluorometyl)N-[2-(trifluorometil)bfenl-2-il]-1H-pirazol-4-carboxamide, (2026) 2-fluoro-6-(trifluorometil)-Nq Lznnn / zznz / E / YiAi (1,1,3-trimetí l-2,3-dih idro-1H-inden-4-il)benzamída, (2027) 3-(dif luorom eti I)-1 -metil-N-(1,1,3trimet¡l-2,3-d¡h¡dro-1H-¡nden-4-¡l)-1H-pirazol-4-carboxam¡da, (2028) inpirfluxam, (2029) 3(difluorometil)-l -metil-N-[(3S)-1,1,3-trimetil-2,3-dihidro-1 H-inden-4-il]-1 H-pirazol-4-carboxamida, (2030)fluindapir, (2031) 3-(difluorometil)-N-(7-fluoro-1,1,3-trimetil-2,3-dihidro-1 H-inden-4-il)-1 methyl-1 H-pirazol-4-carboxamida, (2031) 3-(difluorometil)-N-[(3R)-7-fluoro-1,1,3-trimetil-2,3-dihidro1 H-¡nden-4-¡I]-1-metil-1 H-pirazol-4-carboxamida, (2032) 3-(difluorometil)-N-[(3S)-7-fluoro-1,1,3trimetil-2,3-dihydro-1 H-inden-4-il]-1 -metil-1 H-pirazol-4-carboxamida, (2033) 5,8-difluoro-N-[2-(2fluoro-4-{[4-(tr¡fluorometh¡l)p¡r¡d¡n-2-yl]oxy}phen¡l)et¡l]quinazol¡n-4-amna, (2034) N-(2-cyclopentyl-5fluorobenc¡l)-Nc¡clopropyl-3-(d¡fluorometh¡l)-5-fluoro-1 -methyl-1 H-pyrazol-4-carboxamide, (2035) N(2-tert-butyl-5-meth¡lbenc¡l)-Nc¡cloprop¡l-3-(d¡fluoromethl)-5-fluoro-1-met¡l-1 H-pyrazole-4carboxamide, (2036) N-(2-tert-butylbenc¡l)-Nc¡cloprop¡l-3-(d¡fluorometh¡l)-5-fluoro-1 -methyl-1 Hpyrazol-4-carboxamide, (2037) N-(5-chloro-2-ethylbenc¡l)-Nc¡cloprop¡l-3-(d¡fluoromethyl)-5-fluoro-1methyl-1H-p¡razol-4-carboxam¡da, (2038) isoflucipram, (2039) N-[(1 P,4S)-9-(dichloromethylene)1,2,3,4-tetrahydro-1,4-methanonaphthalene-5-yl]-3-(difluoromet¡l)-1 -methyl-1 H-pyrazole-4-carboxamide, (2040) N-[(1 S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-5-yl]-3-(difluorometh¡l)1 -methyl-1 H-pyrazol-4-carboxamide, (2041) N-[1 -(2,4-dichlorophenium I)-1-3-p luoromethium I) -1 -methyl-1 H-pyrazole-4-carboxamide,(2042) N-[2-chloro-6-(trifluoromethyl)benc¡l]-Ncycloprop¡l-3-(d¡fluorometh¡l)-5-fluoro-1 -methyl-1 H-pyrazole-4-carboxamide, (2043) N-[3-chloro-2-fluoro6-(trifluorometh¡l)benc¡l]-Nc¡cloprop¡l-3-(d¡fluorometh¡l)-5-fluoro-1-methyl-1 H-pyrazole-4-carboxamide, (2044) N-[5-chloro-2-(trifluoromet¡l)benc¡l]-Nc¡cloprop¡l-3-(d¡fluorometh¡l)-5-fluoro-1-methyl-1 Hpyrazol-4-carboxamide, (2045) N-cyclopropy l-3-(d if uorome) lu-5-1 -methyl-N-[5-methyl-2(trifluoromet¡l)benc¡l]-1 H-pyrazol-4-carboxamide, (2046) N-cyclopropyl-3-(d¡fluorometh¡l)-5-fluoro-N(2-fluoro-6-isopropylbenc¡l)-1 -meth-14-prazolida, H-carboxamide (2047) N-cyclopropyl-3(difluorometh¡l)-5-fluoro-N-(2-isoprop¡l-5-methylbenc¡l)-1 -methyl-1 H-pyrazol-4-carboxamide, (2048) Ncycloprop¡l-3-(d¡fluorometh¡l)-5-fluoro-N-(2-¡sopropylbenc¡l)-1-methyl-1 H-pyrazol-4-carbotioamide, (2049) N-cyclopropyl l-3-(d if fluoromethyl)-5-f I uoro-N-propyl-2-iso-bencil-1-1 H-pyrazole-4carboxamide,(2050) N-cyclopropy¡l-3-(d¡fluoromethyl)-5-fluoro-N-(5-fluoro-2-¡sopropylbenc¡l)-1 -methyl1 H-pyrazole-4-carboxamide, (2051) N-cyclopropyl l-3-(d¡if fluoromethyl-l-3-(d¡l-2) and l-2 methylbenzi l)-5fluoro-1 -methyl-1 H-pyrazol-4-carboxamide, (2052) N -cyclopropyl l-3-(dif I uoromethyl)-N-(2-ethyl-5fluorobenzyl)-5-fluoro-1 -methyl-1 H-pyrazol-4-carboxamide, (2053) N-cyclopropyl-3-(d¡fluorometh¡l)-N(2-ethyl-5-methylbenc¡l)-54luoro-1 -methyl-1 H-pyrazol-4-carboxamide, (2054) N-cyclopropyl-N-(2cyclopropyl-5-f luorobenzyl)-3oro-fluoro-(5-fluoro-1) -methyl-1 H-pyrazol-4-carboxamide, (2055) Ncycloprop¡lN-(2-c¡cloprop¡l-5-meth¡lbenc¡l)-3-(d¡fluoromethyl)-5-fluoro-1 -methyl-1 H-pyrazol-4q Lznnn / Ezzn / Exn / A 2055 carboxamide, N-cycloprop¡lN-(2-c¡clopropylbenzyl)-3-(d¡fluorometh¡l)-5-fluoro-1 -methyl-1 Hpyrazol-4-carboxamide, (2057) pyrapropoin, (2058) N¿rac-(1S,2S)-2-(2,4-dichlorophen¡l)c¡clobut¡l]-2(tr¡fluoromet¡l)-n¡cot¡nam¡da, (2059) N-[(1 C,2C)-2-(2,4-dichlorophenyl)cyclobutyl]-2(trifluoromethylnicotinamide;,respiratory chain inhibitors in complex III selected from the group consisting of (3001) ametoctradine, (3002) amisulbrom, (3003) azoxystrobin, (3004) coumethoxystrobin, (3005) coumoxystrobin, (3006) cyazofamide, (3007) dimoxystrobin, (3008) enoxastrobin, (3009) famoxadone, (3010) fenamidone, (3011) fluphenoxystrobin, (3012) fluoxastrobin, (3013) kresoximmethyl, (3014) metominostrobin, (3015) orisastrobin, (3016) picoxystrobin, (3017) pyraclostrobin, (3018) pyramethostrobin, (3019) pyroxystrobin, (3020) trifloxystrobin, (3021) (2E)-2-{2-[({[(1 E)-1 -(3-{[(E)-1 -fluoro-2-phenylvinyl]oxy}phenyl)ethylidene]amino}oxy)methyl]phenyl}-2(methoxymino)-N-methylacetamide, (3022) (2E,3Z)-5-{[1-(4-chlorophenyl)-1 H-pyrazol-3-yl]ox¡}-2(methoxymino)-N,3-dimethylpent-3-enam¡de, (3023) (2R)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2methoxy-N-methylacetamide, (3024) (2S)-2-{2-[(2,5-dimethylphenoxy¡)methyl]phenyl}-2-methoxy¡-Nmethylacetamide, (3025) fenpicoxamide, (3026) mandestrobin,(3027) N-(3-ethyl-3,5,5tr¡met¡lc¡clohex¡l)-3-formamido-2-h¡drox¡benzamide, (3028) (2E,3Z)-5-{[1-(4-chloro-2-fluorophenyl)1 H-pyrazol-3-yl]ox¡}-2-(methoxy¡m¡no)-N,3-d¡met¡lpent-3-enam¡da, (3029) methyl {5-[3-(2,4-dimethylphenyl)1 H-pyrazol-1-yl]-2-meth¡lbenzyl,}methylcarbapromant,(3030) (3031) florylpicoxamide;, inhibitors of cell division and mitosis selected from the group consisting of (4001) carbendazim, (4002) dietophencarb, (4003) etaboxam, (4004) fluopicolide, (4005) pencicuron, (4006) thiabendazole, (4007) methyl thiophanate, (4008); zoxamide, (4009) pyridaclomethyl, (4010) 3chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylp¡ridazine, (4011) 3-chloro-5-(6-chlorop¡ridin-pyridin3-¡l)-6-methyl-4-(2,4,6-tr¡fluorophenyl)pyridazone, (4012) 4-(2-bromo-4-fluorophenyl)-N-(2,6-difluorophenyl)1,3-dimethyl I-1 H-pyrazol-5-amine, (4013) 4-(2-bromo-4-fluorophenyl)-N-(2-bromo-6-fluorophenyl)-1,3dimethyl I-1 H-pyrazol-5-amine, (4014) 4-(2-bromo-4-fluorophenyl)-N-(2-bromophen¡l)-1,3-dimethyl-1 Hpyrazol-5-amine, (4015) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophen¡l)-1,3-d¡met¡l-1 H-pyrazol-5amine, (4016) . 4-(2-bromo-4-fluorophenyl)-N-(2-chlorophen¡l)-1,3-d¡methyl-1H-p¡razol-5-amine, (4017) 4(2-bromo-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1 H-pyrazol-5-amine, (4018); 4-(2-chloro-4fluorophenyl)-N-(2,2) .6-difluorophenyl)-1,3-dimethyl-1 H-pyrazol-5-amine, (4019) 4-(2-chloro-4-fluorophenyl)-N(2-chloro-6-fluorophenyl)-1,3-dimethyl-1-1 H-pyrazol-5-amine, (4020); 4-(2-chloro-4-fluorophenyl)-N-(2chlorophen i I)-1,3-dimethyl-1 H-pyrazol-5-amine, (4021) 4-(2-chloro-4-f I uorophenyl)-N-(2-fluorophenyl)-1,3dimethyl-1 H-pyrazol-5-amine, (4022) . 4-(4-chlorophen¡l)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (4023) N-(2-bromo-6-fluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 H-pyrazol-5-amine, (4024) Nq Lznnn / zznz / E / YiAi (2-bromophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1 H-pyrazol-5-amine, (4025) N-(4-chloro-2,6difluorophenyl)-4-(2-chloro-4-fluorophen¡l)-1,3-dimethyl-1 H-pyrazol-5-amine, (4026)fluopimomide;, Compounds capable of having multi-site action selected from the group consisting of (5.001) Bordeaux mixture, (5.002) captafol, (5.003) captan, (5.004) chlorothalonil, (5.005) copper hydroxide, (5.006) copper naphthenate, (5.007) copper oxide, (5.008) copper oxychloride, (5.009) copper(2+) sulfate, (5.010) dithianone, (5.011) dodine, (5.012) folpet, (5.013) mancozeb, (5.014) maneb, (5.015) metiram, (5.016) metiram-zinc, (5.017) copper oxinate, (5.018) propineb, (5.019) sulfur and sulfur preparations (including calcium polysulfide), (5,020) thiram, (5,021) zineb, (5,022) ziram, (5,023) 6-ethyl-5,7-dioxo-6,7-dihydro-5H-pyrolo[3',4':5,6][1,4]dithieno[2,3c][1,2]thiazol-3-carbonitrile; compounds capable of inducing a defense against the host selected from the group consisting of (6.001) acibenzolar-S-methyl, (6.002) isothianiyl, (6.003) probenazole, (6.004) thiadinol; inhibitors of amino acid and / or protein biosynthesis selected from the group consisting of (7.001) cyprodinyl, (7.002) kasugamycin, (7.003) hydrated kasugamycin hydrochloride, (7.004) oxytetracycline, (7.005) pyrimethanil, (7.006) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-11)quinoline; ATP production inhibitors selected from the group consisting of (8.001) siltiofam; cell wall synthesis inhibitors selected from the group consisting of (9,001) bentiavalicarb, (9,002) dimethomorph, (9,003) flumorph, (9,004) iprovalicarb, (9,005) mandipropamide, (9,006) pirimorph, (9,007) valifenalate, (9,008) (2E)-3-(4-tert-butylphen¡l)-3-(2-chloroprídin-4-¡l)-1(morpholin-4-yl)prop-2-en-1 -one, (9.009) (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridíη-4-yl)-1 -(morpholin-4yl)prop-2-en-1-one. membrane and lipid synthesis inhibitors selected from the group consisting of (10.001) propamocarb, (10.002) propamocarb hydrochloride, (10.003) tolclofos-methyl; melanin biosynthesis inhibitors selected from the group consisting of (11.001) tricyclazole, (11.002) tolprocarb; nucleic acid synthesis inhibitors selected from the group consisting of (12.001) benalaxyl, (12.002) benalaxyl-M (kiralaxyl), (12.003) metalaxyl, (12.004) metalaxyl-M (mefenoxam); signal transduction inhibitors selected from the group consisting of (13.001) fludioxonil, (13.002) iprodione, (13.003) procymidone, (13.004) proquinazide, (13.005) quinoxyfen, (13.006) vinclozoline; compounds capable of functioning as uncouplers selected from the group consisting of (14.001) fluazinam and (14.002) meptyldinocap; q Lznnn / zznz / E / YiAi other fungicides selected from the group consisting of (15.001) abscisic acid, (15.002) benthiazole, (15.003) betoxazine, (15.004) capsicin, (15.005) carvone, (15.006) quinomethionate, (15.007) cufraneb, (15.008) cyflufenamide, (15.009) cymoxanil, (15.010) cyprosulfamide, (15.011) flutianyl, (15.012) fosetyl-aluminum, (15.013) fosetyl-calcium, (15.014) fosetyl-sodium, (15.015) methyl isothiocyanate, (15.016) metrafenone, (15.017) mildiomycin, (15.018) natamycin, (15.019) nickel dimethyldithiocarbamate, (15.020) nitrothal-isopropyl, (15.021) oxamocarb, (15.022) oxathiapiproline, (15.023) oxyphenthiine, (15.024) pentachlorophenol and salts, (15.025) phosphonic acid and its salts, (15.026) propamocarb-fosetylate, (15.027) pyriophenone (clazafenone), (15.028) tebufloquin, (15.029) teclophthalam, (15.030) tolnifanide, (15.031) 1 -(4-{4-[(5R)-5-(2,6difluorophenyl)-4,5-d¡hydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1 -yl)-2-[5-methyl-3-(trifluoromethyl)1-Hylpytanone, -1] (15.032) 1 -(4-{4-[(5C)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3thiazol-2-yl}p¡per¡d¡n-1 -yl)-2-[5-m ethyl-3-luorometryl-1-l -yl]ethanone, (15,033) 2-(6benzylp¡r¡n-2-l)quinazole, (15,034) dipimetritone, (15,035) 2-[3,5-bis(difluoromethl)-1H-prazol1 -yl -[4-(4-{5-[2-(prop-2-in-1 -i loxi )pheny l]-4,5-d¡ h hydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1 yl]ethanone, (15.036) 2-[3,5-dl(d) uromethyl-1 H -yl]-1 -[4-(4-{5-[2-chloro-6-(prop-2-in-1 i loxi)phen yl]-4,5-d¡ h id ro-1,2-oxazol-3-yl}-1,3-thiazol-2-i I) p¡ peri of n-1 -yl]ethanone, (15.03) 2-[3,5bis(difluoromethyl)-1 H-pyrazol-1 -yl]-1 -[4-(4-{5-[2-fluoro-6-(prop-2-in-1 -yloxy)phenyl]-4,5-d¡ hydro-1,2oxazol-3-yl}-1,3-thiazol-2-ylpitanone-1,] (15.038) 2-[6-(3-fluoro-4-methoxyphenyl)-5methylpyridi n-2-¡ l]quinazole¡ na, (15.039) 2-{(5R)-3-[2-(1 -{[3,5-bis(dif luoromethyl)-1 H-pyrazole-1 yl]acet¡l}p¡perid¡n-4-¡l)-1,3-thiazol-4-¡l]-4,5-d¡h¡dro-1,2-oxazol-5-yl}-3-chlorophenyl methanosulf onate, (15.040) 2-{(5S)-[2-(2-(3-{)-(if luoromethi l)-1 H-pyrazol-1 -yl]acetyl}piperidi η-4-i I)-1,3-thiazol-4-yl]4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanosulfonate, (15.041) 2-{2-[(7,8-difluoro-2methylquol¡na-3-yl)ox¡]-6-fluorophen¡l}propan-2-ol, (15.042) 2-{2-fluoro-6-[(8-fluoro-2-methylquinol¡na3-¡l)oxy]-phenyl-2-4.5. fluoxapiproline, (15,044) 2-{3-[2-(1-{[3,5-bis(difluorometh¡l)-1 Hpyrazol-1 -yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-ylphone, I (15,045) 2-phenylphenol and its salts, (15,046) 3-(4,4,5-tr¡fluoro-3,3-d¡meth¡l-3,4-d¡h¡droisoquinol¡n-1 ¡l)quinoline, (15,047) quinoline, (15,044) 4-amino-5-fluoropyr¡m¡d¡n-2-ol (tautomeric form: 4amino-5-fluoropyr¡m¡d¡n-2(1H)-one), (15.049) 4-oxo-4-[(2-phenylethyl)am¡no] butanoic acid, (15,050) 5-amino-1,3,4-thiadiazol-2-t¡ol, (15,051) 5-chloro-N'-phenyl-N'-(prop-2-¡n-1-hydrophospho-2), (15,052) 5-fluoro-2-[(4-fluorobenzyl)ox¡]p¡r¡m¡n-4-amine, (15,053) 5-fluoro-2-[(4methylbenc¡l)ox¡]p¡r¡m¡n-4-m¡n-4-4-amine (15,5.5) 9-fluoro-2,2-d¡ methyl-5-(quinol¡n-3-¡ I )-2,3-dih hydro-1,4benzoxazepine, (15,055) but-3-in-1-II {6-[({[(Z)-(1-methyl-1 H-tetrazolium-5¡I) (phenoid) l]p¡ rid i n-2-yl}carbamate, (15,056) ethyl (2Z)-3-amino-2-cyano-3q Lznnn / zznz / E / YiAi phenylacrylate, (15,057) phenazine-1-carboxylic acid, (15,058) 3,3,hydroxyl, dehydroxyl-debenyl, (15,056) (15.059) quinoline-8-ol, (15.060) quinoline-8-ol sulfate (2:1), (15.061) tert-butyl {6-[({[(1-methyl-1 Htetrazol-5-¡l)(phen¡l)methylene]am¡no}ox¡)meth¡l]p¡r¡d¡n-2-¡l}carbamate, (15.062) 5-fluoro-4-imino-3-met¡l1-[(4-methylphen¡l)sulfonyl]-3,4-d¡hydropyrim¡din-2(1 H)-one, (15,063) aminopyrifhene, (15.064) (N'-[2chloro-4-(2-fluorophenox¡)-5-methylphen¡l]-N-et¡lN-methylim¡doform¡da), (15,065) (N'-(2-chloro-5-methyl4-phenoxyphenyl)-N-ethyl-N-formam0methyl¡6)mide (2-{2-[(7,8-difluoro-2-methylquinoline-3-yl)oxy]6-fluorophenyl}propane-2-ol), (15,067) (5-bromo-1 -(5,6-di methylp ridi η-3-i I )-3,0-dimethylpyridi η-3-lino)1,4.4 (3-(4,4-difluoro-5,5-dimethyl-4,5-dihydrothiene[2,3-c]pyridine-7yl)qu ¡noli na), (15,069) (1 -(4,5-dimethy 1-1 H-benzimidazol-1 -yl)-4,4-isohydro-3-quinohydryl,methylhydrodine,3 (15,070) 8-fluoro-3-(5-fluoro-3,3-dimeth¡l-3,4-d¡h¡droisoquinol¡n-1 -yl)quinolone, (15,071) 8-fluoro-3-(5-fluoro-3,3,4,4-dromo-tetraquysodyl¡n¡h -yl)quinolone, (15,072) 3(4,4-difluoro-3,3-dimethyl-3,4-dih¡droisoqu¡nol¡n-1 -yl)-8-fluoroquinol¡n, (15,073) (N-methyl-N-phenyl-4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzam¡da), (15,074) methyl {4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phenyl}carbamate, (15075) (N-{4-[5-(trifluorometil)-1,2,4-oxadiazol-3¡l]bencil}c¡clopropanocarboxamida), (15.076) N-metí l-4-(5-(trifl uorometi l)-1,2,4-oxadiazol-3il]benzamida, (15.077) N-[(E)-metoxi¡m¡nometil]-4-[5-(tr¡fluoromet¡l)-1,2,4-oxadiazol-3il]benzamida, (15.078) N-[(Z)-metoxi¡m¡nometil]-4-[5-(tr¡fluoromet¡l)-1,2,4-oxadiazol-3il]benzamida, (15.079) N-[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-¡l]fen¡l]ciclopropanocarboxamida, (15.080) N-(2-fluorofenil)-4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il]benzamida, (15.081) 2,2difluoro-N-metil-2-[4-[5-(trifluorometil)-1,2,4-oxadiazol-3-¡l]fenil]acetamida, (15.082) N-alilo-N-[[4[5-(trifluoromet¡l)-1,2,4-oxadiazol-3-¡l)fen¡l]met¡l]acetamida, (15.083) N-[(E)-N-metoxi-C-metilcarbonim idoil]-4-(5-(trif luorometil)-1,2,4-oxadiazol-3-il]benzam¡da, (15.084) N-[(Z)-N-metoxi-Cmetil-carbonimidoil]-4-[5-(trifluorometiI)-1,2,4-oxadiazol-3-il]benzamida, (15.085) N-alilo-N-[[4-[5(trifluorometil)-l ,2,4-oxadiazol-3-¡l]fen¡l]metil]propanam¡da, (15.086) 4,4-dimetil-1 -[[4-[5(trifluorometiI)-1,2,4-oxadiazol-3-¡l]fen¡l]met¡l]p¡rrolid¡n-2-ona, (15.087) N-metil-4-[5-(trifluoromet¡l)1,2,4-oxadiazol-3-il]bencenocarbotioamida, (15.088) 5-metil-1 -[[4-[5-(trifluorometil)-1,2,4oxadiazol-3-¡ l]fenil]metil]pirrolid¡ n-2-ona, (15.089) N-((2,3-difluoro-4-[5-(trifluorometil)-1,2,4oxadiazol-3-il]fen¡l]met¡l]-3,3,3-trifluoro-propanam¡da, (15.090) 1 -metox¡-1 -metil-3-[[4-[5(trifluorometil}-1,2,4-oxadiazol-3-il]fen¡l]met¡l]urea, (15.091) 1,1 -dietil-3-[[4-[5-(tr¡fluoromet¡l}-1,2,4oxadiazol-3-il]fenil]met¡l]urea, (15.092) N-[[4-[5-(trifluorometil)-1,2,4-oxadiazol-3il]fenil]metil]propanam¡da, (15.093) N-metoxi-N-[[4-[5-(trifluoromet¡l)-1,2,4-oxadiazol-3il]fenil]metil]c¡clopropanocarboxamida, (15.094) 1 -metox¡-3-met¡l-1 -[[4-[5-(trif luorometil)-1,2,4oxadiazol-3-il]fen¡l]met¡l]urea, (15.095) N-metoxi-N-[[4-[5-(trifluoromet¡l)-1,2,4-oxadiazol-3q ίζηηη / ζζηζ / Ε / γίΛΐ ¡l]fen¡l]metil)c¡clopropanocarboxam¡da, (15.096) N,2-dimethoxy-N-[[4-[5-(tr¡fluorometh¡l}-1,2,4oxadiazol-3-yl]phen¡l]meth¡l]propanam¡da, (15,097) N-ethyl-2-methyl-N-[[4-[5-(tr¡luorometh¡l}-1,2,2,2) Lznnn / zznz / E / YiAi in oxadiazol-3-yl)phen¡l]meth¡l]propanam¡da, (15,098) 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1,2,4oxadiazol-3-yl]phen¡l]phen¡l], (15,998). 1,3-d¡methox¡-1 -[[4-[5-(trif luorom ethy I)-1,2,4-oxadiazol-3yl]f enyl]met¡ l]u rea, (15.100) 3-ethyl 1-1 -methox¡-1 -[[4-[5-(trif uorometh I) l)-1,2,4-oxadiazol-3 yl]phenyl]methyl]urea, (15.101) 1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-¡l]phenyl]methyl]p¡per¡din-2-one, (15.102) 4,4-dimethl-2-[[4-[5-(trifluoromethl)-1,2,4-oxadiazol-3-¡l]phen¡l]meth¡l]¡sooxazolid¡n-3-one, (15.103) 5,5-dimethyl-2-[[4-[5-(tr¡fluorometh¡l)-1,2,4-oxad¡azol-3-yl]phen¡l]meth¡l]¡soxazol¡n-3-one, (15.104) 3,3-dimethyl-1 -[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-¡l]phen¡l]met¡l]p¡per¡din-2-one, (15.105) 1-[[3-fluoro-4-(5-(tr¡fluoromet¡l)-1,2,4-oxad¡azol-3-yl]phen¡l]meth¡l]azepan-2-one, (15.106) 4,4-dimethyl2-[[4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-¡l]phen¡l]met¡l]¡soxazol¡din-3-one, (15.107) 5,5-dimethyl-2-[[4[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]meth¡l]isoxazolidin-3-one, (15,108) ethyl 1 -{4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-l}-l}-l H-pyrazole-4-carboxylate, (15.109) N,N-dimethyl-1 -{4-[5(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzyl}-1 H-1,2,4-triazole-3-amine, (15.110) N-{2,3-difluoro-[5. -1,2,4-oxadiazol-3-yl]benc¡l}butan¡da, (15.111) N-(1 -methylc¡cloprop¡l)-4-[5(trifluoromethyI)-1,2,4-oxadiazol-3-yl]benzam¡da, (15.111) N-(2,2) uro-f yl)-4-[5-(trif luoromethyl I)1,2,4-oxadiazol-3-yl]benzamide, (15,113) 1 -(5,6-d¡ methi lpyridin-3-yl)-4,4-dif luoro-3,3-d¡ methyl-3,4dihydroquinoline, (141) 1.1. -(6-(difl uoromethyl)-5-meth¡ l-pyridin-3-yl)-4,4-difluoro-3,3-di methyl-3,4dihydroisoquinoline, (15.115) 1 -(5-(fl uoromethyl)-6-methy I-pyridi n-3-yl)-4,4-difluoro-3,3-lume I-3,4dihydroisoquinoline, (15(116) 1 -(6-(difluoromethyl)-5-methox¡-pyridin-3-yl)-4,4-difluoro-3,3-dimethyl-3,4dihydroisoqui noline, (15,117) 4-[5-(trifluoromethyl)-1,2,4carba-matomethyl-oxadia (15,118) N-{4-[5-(trifluoromet¡l)-1,2,4-oxadiazol-3-yl]phen¡l}propanam¡da, (15,119) 3-[2-(1 -{[5-methyl3-(trifluoromethyl)-1 H-pyrazol]acet-1 l}piper¡d¡n-4-yl)-1,3-thiazol-4-yl]-1,5-dihydro-2,4-benzodioxep¡n6-yl methanosulfonate, (15,120) 9-fluoro-3-[2-(1-{[5-methyl-3-(trifluoromethyl) il]acetyl}p¡peridin-4-yl)-1,3-thiazol-4-yl]-1,5-dihydro-2,4-benzod¡n-6-¡l methanosulfonate, (15,121) 3-[2-( 1 -{[3,5-bis(difluoromethyl-1- I) -yl]acetyl}piperid and η-4-yl)-1,3-thiazol-4-yl]-1,5-d¡ hydro-2,4benzodioxepin-6-yl methanosulfonate, (15,122) 3-[2-(1 -{[3,5-bis(difluoromethyl)- il]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-9-fluoro-1,5-dihydro-2,4-benzod¡oxepin-6-¡l methanosulfonate, (15.123) 1 -(6,7-dimethi lpyrazolo[1,5-a]pyridi n-3-yl)-4,4-dif I uoro-3,3-dimethyl-3,4-dih idroisoqu ¡noline, (15.124) 8-fluoro-N-(4,4,4-trifluoro-2-methyl-1-phenylbutan-2-yl)quinoline-3-carboxamide, (15.125) N-(2,4dimethyl-1-phenylpentan-2-l)-8-fluoroquinolin-3-carboxamide and (15.127) N-[(2S)-2,4-dimethyl-127 phenylpentan-2-yl]-8-fluoroquinoline-3-carboxamide. Chemical pesticide mixture partner (b) The active compounds identified here by their common names are known and described, for example, in the pesticide manual (“The Pesticide Manual”, 16th Ed., British Crop Protection Council 2012) or can be found online (e.g., http: / / www.alanwood.net / pesticides). The classification is based on the IRAC Mode of Action Classification Scheme applicable at the time of filing this patent application. In a further embodiment of the invention, the active compound combinations comprise (a) Bacillus spp. strain NRRL B-67746 or a plant growth-promoting mutant of this strain and at least one compound (b) selected from the following groups. (1) Acetylcholinesterase (AChE) inhibitors, preferably carbamates selected from alanicarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, etiofencarb, fenobucarb, formetanate, furatiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiophanox, triazamate, trimetacarb, XMC and xylylcarb;or selected organophosphates of acetate, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusaphos, chlorethoxyphos, chlorfenvinphos, chlormephos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, fanfur, fenamidos, fenitrothion, fenthion, fosthiazate, heptenophos, imiciaphos, isofenphos, isopropyl O-(methoxyamynothiophosphoryl) salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, ometoate, methyl oxidemeton, methyl parathion, fenthoate, phorate, phosalone, phosmet, phosphamidon, phosphime, methyl pirimiphos, profenofos, propetamphos, prothiophos, pyraclophos, pyridafenthion, quinalfos, sulfotep, tebupirimphos, temephos, terbuphos, tetrachlorvinphos, thiometon, triazophos, trichlorfon and vamidotithion.; (2) GABA-dependent chloride channel blockers, preferably cyclodiene organochlorines selected from chlordane and endosulfan, or phenylpyrazoles (fiproles) selected from etiprol and fipronil. (3) Sodium channel modulators, preferably pyrethroids selected from acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, bioallethrin scyclopentenylisomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyfenothrin [(1R)-trans isomer], deltamethrin, empentrin [(EZ)-(1R) isomer], esfenvalerat, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, momfluorothrin, permethrin, phenothrin q Lznnn / zznz / E / YiAi [(1R)-trans isomer], praletrin, pyrethrin (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R) isomer], tralomethrin and transfluthrin or DDT or methoxychlor. (4) Competitive modulators of the nicotinic acetylcholine receptor (nAChR), preferably neonicotinoids selected from acetamipride, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam, or nicotine, or sulfoximines selected from sulfoxaflor, or butenolides selected from flupyradifurone, or mesoionics selected from triflumezopyrim. (5) Allosteric modulators of the nicotinic acetylcholine receptor (nAChR) (Site I), preferably spinosines selected from spinetoram and spinosad. (6) Allosteric modulators of glutamate-dependent channels (GluCI), preferably avermectins / milbemycins selected from abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Juvenile hormone mimics, preferably juvenile hormone analogues selected from hydroprene, cinperene and methoprene or phenoxycarb or pyriproxyfen. (8) Miscellaneous non-specific (multi-site) inhibitors, preferably alkyl halides selected from methyl bromide and other alkyl halides, or chloropicrin or sulfuryl fluoride or borax or tartar emetic or methyl isocyanate generators selected from diazomet and metam. (9) Modulators of the TRPV channel of accordion organs, preferably pyridine azomethanes selected from pymetrozine and pyrifluquinazone, or pyropenes selected from afidopyropene. (10) Mite growth inhibitors affecting CHS1 selected from clofentezine, hexythiazox, diflovidazine, and etoxazole. (11) Insect intestinal membrane microbial disruptors selected from Bacillus thuringiensis israelensis subspecies, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis kurstaki subspecies, Bacillus thuringiensis tenebrionis subspecies, and Bt plant proteins selected from Cry1 Ab, Cry1 Ac, Cry1 Fa, Cry1 A.105, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb and Cry34Ab1 / 35Ab1. (12) Mitochondrial ATP synthase inhibitors, preferably ATP disruptors selected from diaphenthiuron compounds, or organotin compounds selected from azocyclotine, cyhexatine and phenbutatine oxide, or propargite or tetradiphon. (13) Oxidative phosphorylation uncouplers through proton gradient disruption selected from chlorfenapyr, DNOC and sulfluramide. (14) Nicotinic acetylcholine receptor channel blockers selected from bensultap, cartap hydrochloride, thiocyclam and sodium thiosulfate. q Lznnn / zznz / E / YiAi (15) Chitin biosynthesis inhibitors affecting CHS1 preferably benzoylureas selected from bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron. (16) Chitin biosynthesis inhibitors, type 1, selected from buprofezin. (17) Molting disruptor (particularly for Diptera, i.e., flies) selected from cyromazine. (18) Ecdysone receptor agonists, preferably diacylhydrazines selected from chromafenozide, halofenozide, methoxyfenozide and tebufenozide. (19) Selected octopamine receptor agonists from amitraz. (20) Selected mitochondrial inhibitors of complex III electron transport from hydramethylnon, acequinocil, fluacripyrim, and bifenazate. (21) Mitochondrial inhibitors of complex I electron transport, preferably METI acaricides and insecticides selected from phenazaquine, fenpyroximate, pirimidifene, pyridaben, tebufenpyrad and tolfenpyrad or rotenone (Derris). (22) Voltage-dependent sodium channel blockers, preferably oxadiazines selected from indoxacarb, or semicarbazones selected from metaflumizone. (23) Acetyl CoA carboxylase inhibitors, preferably tetronic and tetramic acid derivatives selected from spirodiclofen, spiromesifen, spiropidion and spirotetramate. (24) Mitochondrial inhibitors of complex IV electron transporters, preferably phosphides selected from aluminum phosphite, calcium phosphite, phosphine and zinc phosphite, or cyanides selected from calcium cyanide, potassium cyanide and sodium cyanide. (25) Complex II electron transport mitochondrial inhibitors, preferably befa-ketonitrile derivatives selected from cyenopyrafen and cyflumethophen, or carboxanilides selected from piflubumid. (28) Ryanodine receptor modulators, preferably selected diamides of chlorantraniliprole, cyantraniliprole, cyclaniliprol, flubendiamide and tetraniliprol. (29) Chordotonal organ modulators (with undefined target site) selected from flonicamid. (30) Allosteric modulators of GABA-activated chloride channels, preferably selected metadiamides of broflanilide, or selected isoxazoles of fluxamethamide. (31) Baculoviruses, preferably Granuloviruses (GVs) selected from Cydia pomonella GV andThaumatotibia leucotreta (GV), or Nucleopolyhedroviruses (NPVs) selected fromAnticarsia gemmatalis MNPV and Helicoverpa armigera NPV. q Lznnn / zznz / E / YiAi (32) Acetylcholine nicotinic receptor (Site II) allosteric modulators selected from GS-omega / kappa peptide HXTX-Hv1 a. (33) additional active compounds selected from acinonapyr, afoxolaner, azadirachtin, benzclothiaz, benzoximate, benzpyrimoxan, bromopropylate, quinomethionate, chloropralethrin, cryolite, cyclobutyrifluram or cyclobutylene (CAS 1460292-16-3), cycloxaprid, cietpyrafen, cyhalodiamide, dichloromezothiaz, dicofol, dimpropyridaz, epsilon-metofluthrine, epsilon-momfluthrine, phlomethoquine, fluazaindolizine, fluensulfone, flufenerim, fluphenoxystrobin, flufiprol, fluhexafon, fluopyram, fluralaner, fufenozide, fupentiofenox (CAS 1472050-04-6), guadipyr, heptafluthrine, imidaclotiz, iprodione, Isocycloseram, kappa-bifenthrin, kappa-tefluthrin, lotilaner, meperfluthrin, oxazosulfin, paichongding, pyridalyl, pyrifluquinazone, pyriminostrobin, spirobudiclofen, tetramethylfluthrin, tetrachlorantraniliprole, tigolanor, thioxazafen, thiofluoximate, iodomethane, triflupentoxide (CAS 1472050-04-6); in addition, preparations based on Bacillus firmus^A 582, BIONEEM®, VOTIVO®),and also the following compounds: 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl}-3(trifluoromethyl)-1H-1,2,4-triazole-5-amine (known from WO 2006 / 043635) (CAS 885026-50-6), {1'-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indol-3,4'-piperidin]-1(2H)-yl}(2chloropyridin-4-yl)methanone (known from WO 2003 / 106457) (CAS 637360-23-7), 2chloro-N-[2-{1-[(2E)-3-(4-chlorophenl)prop-2-en-1-¡l]p¡per¡din-4-¡l}-4-(trifluoromethyl)phen¡l]¡son¡cotinamide (known from document WO 2006 / 003494) (CAS 872999-66-1), 3-(4-chloro-2,6-dimethylphenyl)-4hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from WO 2010 / 052161) (CAS 1225292-17-0), 3-(4-chloro-2,6-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl ethyl carbonate (known from document EP 2647626) (CAS 1440516-42-6), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from document WO 2004 / 099160) (CAS 792914-58-0),PF1364 (document document JP 2010 / 018586) (CAS 1204776-60-2), (3E)-3[1 -[(6-chloro-3-pyridyl)methyl]-2-pyridylideno]-1,1,1 -trifluoro-propan-2-one (document document WO 2013 / 144213) (CAS 1461743-15-6), , N-[3-(benzylcarbamoyl)-4-chlorophen¡l]-1-met¡l-3(pentafluoroethyl)-4-(trifluoromethyl)-1 H-pyrazole-5-carboxamida (document document WO 2010 / 051926) (CAS 1226889-14-0), 5-bromo-4-chloro-N-[4-chloro-2-methyl-6-(methylcarbamo¡l)phen¡l]-2(3-chloro-2-pyrid¡l)p¡razol-3-carboxam¡da (document code CN 103232431) (CAS 144922044-3), 4-[5-(3,5-d¡chlorofen¡l)-4,5-dih¡dro-5-(tr¡fluoromet¡l)-3-¡soxazol¡l]-2-met¡lN-(c¡s-1-ox¡do-3thietanyl)-benzamida, 4-[5-(3,5-d¡chlorofen¡l)-4,5-d¡h¡dro-5-(tr¡fluoromethyl)-3-isoxazol¡l]-2-met¡lN(trans-1-oxido-3-thietan¡l)-benzam¡da y 4-[(5S)-5-(3,5-dichlorofen¡l)-4,5-d¡hidro-5-(tr¡fluoromet¡l)-3¡soxazolyl]-2-met¡lN-(cis-1 -oxido-3-thietanyl)benzam¡da (according to document WO 2013 / 050317 A1) (CAS 1332628-83-7),N-[3-chloro-1-(3-pyridin¡l)-1 H-pyrazol-4-¡l]-N-eth¡l-3-[(3,3,3- q Lznnn / zznz / E / YiAi trifluoropropyl)sulfinyl]-propanamida, (+)-N-[3-chloro-1-(3-pyridin¡l)-1H-pyrazol-4-yl]-N-eth¡l-3-[(3,3,3trifluoroprop¡l)sulf¡n¡l]-propanam¡da y (-)-N-[3-chloro-1 -(3-pyridinyl)-1 H-pyrazol-4-yl]-N-et¡l-3-[(3,3,3tr¡fluoroprop¡l)sulf¡n¡l]-propanamida (knowledge of the WO document 2013 / 162715 A2, WO 2013 / 162716 A2, Publicación de Solicitud de Patente de los EE. UU. No. 2014 / 0213448 A1) (CAS 1477923-37-7), 5-[[(2E)-3-chloro-2-propene-1 -yl]amino]-1 -[2,6-dichloro-4-(trif luoromethyl)pheni l]-4[(trifluoromethyl)sulfin¡l]-1 H-pyrazol-3-carbonitrilo (document code CN 101337937 A) (CAS 1105672-77-2), 3-bromo-N-[4-chloro-2-methyl-6-[(met¡lam¡no)t¡oxomet¡l]phen¡l]-1 -(3-chloro-2-pyridinyl)1 H-pyrazol-5-carboxamida, (Liudaibenjiaxuanan, document number CN 103109816 A) (CAS 1232543-85-9); N-[4-chloro-2-[[(1,1 -dimethylethyl)amino]carbonyl]-6-methylphenyl]-1 -(3-cloiO-2-pyridinyl)-3(fluoromethoxy)-l H-irazol-5-carboxamida (document document WO 2012 / 034403 A1) (CAS 1268277-22-0), N-[2-(5-amino-1,3,4-thiadiazol-2-l)-4-chloro-6-met¡lfen¡l]-3-bromo-1 -(3-chloro-2pyrid¡n¡l)-1 H-pyrazol-5-carboxamida (document document WO 2011 / 085575 A1) (CAS 1233882-22-8), 4-[3-[2,6-dichloro-4-[(3,3-d¡chloro-2-propen-1-¡l)ox¡]phenox]propox¡]-2-methox¡-6(trifluorometh¡l)-pyrimid¡na (document code CN 101337940 A) (CAS 1108184-52-6); (2E)y 2(Z)-2-[2-(4-c¡anofen¡l)-1-[3-(tr¡fluorometh¡l)phenyl]et¡l¡deno]-N-[4-(d¡fluoromethox¡)phen¡l]hidrazinecarboxamida (known in document CN 101715774 A) (CAS 1232543-85-9); 3-(2,2dichloroetenil)-2,2-dimet¡l-4-(1 H-benzim¡dazol-2-¡l)fen¡l-éster de ácido ciclopropanecarboxylico (conocide del documento CN 103524422 A) (CAS 1542271-46-4); (4aS)-7-cloro-2,5-dihidro-2[[(methox¡carbon¡l)[4-[(tr¡fluorometil)t¡o]fen¡l]am¡no]carbon¡l]-¡ndeno[1,2-e][1,3,4]oxadiazina-4a(3H)metiléster de ácido carboxílico (conocido del documento CN 102391261 A) (CAS 1370358-69-2); 6-deoxi-3-O-ethyl-2,4-d¡-O-met¡l-, 1 -[N-[4-[1 -[4-(1,1,2,2,2-pentafluoroetoxi)fenil]-1 H-1,2,4-triazol-3¡l]fenil]carbamato]-aL-manopiranosa (conocido del documento Publicación de Solicitud de Patente de los EE. UU. Nro. 2014 / 0275503 A1) (CAS 1181213-14-8); 8-(2-cyclopropylmethoxy-4-tr¡fluoromet¡l-fenoxy)-3-(6-tr¡fluoromet¡lp¡r¡daz¡n-3-yl)-3-aza-b¡c¡clo[3.2.1 ]octane (CAS 1253850-564), (8-anti)-8-(2-c¡clopropylmethoxy-4-tr¡fluoromet¡l-fenoxy)-3-(6-tr¡fluoromethyl-pyridaz¡n-3-¡l)-3-azabicyclo[3.2.1]octane (CAS 933798-27-7), (8-syn)-8-(2-cyclopropylmethoxy-4-trifluoromethylphenoxy)-3-(6-trifluoromethyl-pyr¡dazin-3-¡l)-3-aza-b¡cyclo[3.2.1]octane (document document WO 2007 / 040280 A1, WO 2007 / 040282 A1) (CAS 934001-66-8), N-[3-chloro-1 -(3-pyridinyl)-1 H-pyrazol4-¡l]-N-ethyl-3-[(3,3,3-tr¡fluoroprop¡l)t¡o]-propanam¡da (according to document WO 2015 / 058021 A1,WO 2015 / 058028 A1) (CAS 1477919-27-9) and N-[4-(aminot¡oxomet¡l)-2-met¡l-6[(metilam¡no)carbon¡l]phenyl]-3-bromo-1 -(3-chloro-2-pyridines I)-1 H-pyrazol-5-carboxamide (document name CN 103265527 A) (CAS 1452877-50-7), 5-(1,3-dioxan-2-yl)-4-[[4(trifluoromet¡l)phen¡l]methox¡l]-p¡r¡m¡dine (document name WO 2013 / 115391 A1) (CAS, 1449021 -97-9), 3-(4-chloro-2,6-d¡methylIphenyl)-8-methox¡-1 -methyl-1,8-diazaspiro[4.5]decane-2,4-d¡ona (according to document WO 2014 / 187846 A1) (CAS 1638765-58-8), 3-(4-chloro-2,6-dimethylfen¡l)8-methoxy-1-methyl-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-¡l-et¡léster de ácido carbonico (document recognition O 2010 / 066780 A1, WO 2011151146 A1) (CAS 1229023-00-0), 4-[(5S)-5-(3,5-dichloro4-fluorophen¡l)-4,5-d¡h¡dro-5-(trifluoromet¡l)-3-¡soxazol¡l]-N-[(4R)-2-et¡l-3-oxo-4-¡soxazol¡d¡n¡l]-2methyl-benzamida (document information WO 2011 / 067272, WO 2013 / 050302) (CAS 130995962-3). Organic active ingredients as a medical partner (b) In a further embodiment of the invention, the active compound combinations comprise (a) Bacillus spp. strain NRRL B-67746 or a plant growth-promoting mutant of this strain and at least one compound (b) selected from biologically active compounds, such as biological fungicides or pesticides or plant growth-promoting compounds. The biologically active compounds include, in particular, bacteria, fungi, yeasts, plant extracts, and products formed by microorganisms, including proteins and secondary metabolites. As used in this document, the expression “biological control” is defined as the control of harmful organisms, such as fungi, insects and / or mites and / or phytopathogenic nematodes, by the use or employment of an active compound. As used herein, the term “biologically active compound” is defined as an organism other than the harmful organisms and / or proteins or secondary metabolites produced by that organism, for the purpose of biological control or plant growth promotion. Mutants of the latter organism are included within the definition of the biologically active compound. The term “mutant” refers to a variant of the original strain, as well as to methods for obtaining a mutant or a variant in which the pesticidal activity is greater than that expressed by the original strain. The “original strain” is defined herein as the original strain before mutagenesis. To obtain such mutants, the original strain may be treated with a chemical, such as N-methyl-N'-nitro-N-nitrosoguanidine, ethyl methanesulfone, or by irradiation using gamma rays, X-rays, or UV radiation, or by other means known to those skilled in the art.Known mechanisms of action of biological control compounds include enteric bacteria that control root rot by outcompeting the fungus for space on the root surface. Bacterial toxins, such as antibiotics, have been used to control pathogens. The toxin can be isolated and applied directly to the plant, or the bacterial species can be administered so that it produces the toxin in situ.

[0052] A “variant” is a strain that has all the identifying characteristics of the NRRL or ATCC accession numbers, as stated in this text, and can be identified as possessing a genome that hybridizes under high-stricity conditions with the genome of the NRRL or ATCC accession numbers. The term “hybridization” refers to a reaction in which one or more polynucleotides react to form a complex stabilized by hydrogen bonds between the bases of the nucleotide residues. Hydrogen bonding can occur through Watson-Crick base pairing, Hoogstein bonding, or any other specific sequential mechanism. The complex may consist of two strands forming a duplex structure, three or more strands forming a multistrand complex, a single self-hybridizing strand, or any combination thereof. Hybridization reactions can be carried out under varying “strict” conditions. Generally, a low-strict hybridization reaction is performed at approximately 40 °C in 10⁻¹¹ SSC or a solution of equivalent ionic concentration / temperature.In general, a moderately stringent hybridization is carried out at approximately 50 °C in 6 X SSC and, in general, a highly stringent hybridization reaction is carried out at approximately 60 °C in 1 X SSC. A variant of the indicated NRRL or ATCC accession number can also be defined as a strain having a genomic sequence that exceeds 85%, more preferably greater than 90%, or more preferably greater than 95% sequence identity with the genome of the indicated NRRL or ATCC accession number. A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) having a certain percentage (e.g., 80%, 85%, 90%, or 95%) of “sequence identity” with another sequence means that, when aligned, that percentage of bases (or amino acids) are the same when comparing the two sequences. This alignment and the percentage of homology or sequence identity can be determined using software programs known in the technique, for example, those described in Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987). NRRL stands for Agriculture Research Service Culture Collection, an international depository authority whose purpose is to collect strains of microorganisms under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Proceedings, whose address is National Agricultural Utilization Research Center, Agricultural Research Service, United States Department of Agriculture, 1815 North University Street, Peroira, Illinois 61604, USA. ATCC stands for American Type Culture Collection, an international deposit authority whose purpose is to collect strains of microorganisms under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Proceedings, whose address is ATCC Patent Depository, 10801 University Boulevard, Manassas, VA 10110, USA. The biologically active compound may be a compound with bactericidal activity. Such biologically active compounds with bactericidal activity comprise (A1) bacteria, such as (A1.1) Bacillus subtilis, in particular, strain QST713 / AQ713 (available as SERENADE® OPTI or SERENADE® ASO from Bayer CropScience LP, US, which has accession no. NRRL B-21661, U.S. patent no. 26,060,051); (A1.2) especially Bacillus, in particular, strain D747 (available as DOUBLE NICKEL® from Kumiai Chemical Industry Co., Ltd.), which has accession no. FERM BP-8234, U.S. patent no. 27,094,592; (A1.3) Bacillus pumilus, in particular strain BU F-33, which has accession no. NRRL 50185 (available as part of BASF's CARTISSA® product, EPA registration no. 271840-19); (A1.4) Bacillus subtilis var. amyloliquefaciens strain FZB24 having accession no. 2 DSM 10271 (available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA registration no. 270127-5); (A1.5) a strain of esp.Paenibacillus with accession no. NRRL B-50972, or accession no. 2NRRL B-67129, WO 2016 / 154297; (A1.6) Bacillus subtilis strain BU1814, (available as VELONDIS® EXTRA from BASF SE); (A1.7) Bacillus mojavensis strain R3B (accession n.2NCAIM (P) B001389) (WO 2013 / 034938) from Certis USA LLC, a subsidiary of Mitsui & Co.; (A1.8) Bacillus subtilis CX-9060 from Certis USA LLC, a subsidiary of Mitsui & Co.; (A1.9) Paenibacillus polymyxa, in particular, strain AC-1 (e.g., TOPSEED® from Green Biotech Company Ltd.); (A1.10) Pseudomonasproradix(e.g., PRORADIX® from Sourcon Padena); (A1.11) Pantoea agglomerans, in particular, strain E325 (accession n.2NRRL B-21856) (available as BLOOMTIME BIOLOGICAL™ FD BIOPESTICIDE from Northwest Agri Products); and (A2) fungi, such as (A2.1) Aureobasidium pullulans strain DSM14940, strain DSM14941 or mixtures of strains DSM14940 and DSM14941 (e.g., BOTECTOR®and BLOSSOM PROTECT®by Bio-Ferm, CH); (A2.2) Pseudozyma aphldis (as revealed in document WO 2011 / 151819 by Yissum Research Development Company of the Hebrew University of Jerusalem); (A2.3) Saccharomyces cerevisiae, in particular, the cepas CNCM η.21-3936, CNCM η.21-3937, CNCM η.21-3938 or CNCM η.21-3939 (WO 2010 / 086790) de Lesaffre et Compagnie, FR. q Lznnn / zznz / E / YiAi The biologically active compound may be a biologically active compound with fungicidal activity or a biologically active compound active against oomycetes. Such biologically active compounds comprise (B1) bacteria, for example (B1.1) Bacillus subtilis, in particular, strain QST713 / AQ713 (available as SERENADE® OPTI or SERENADE® ASO from Bayer CropScience LP, US, which has NRRL accession no. B-21661 and is described in U.S. patent no. 26,060,051); (B1.2) Bacillus pumilus, in particular, strain QST2808 (available as SONATA® from Bayer CropScience LP, US, which has NRRL accession no. B-30087 and is described in U.S. patent no. 6,245,551); (B1.3) Bacillus pumilus, in particular, strain GB34 (available as YIELD SHIELD® from Bayer AG, DE); (B1.4) Bacillus pumilus, in particular, strain BU F-33, (which has accession no. NRRL 50185 (available as part of the product CARTISSA® from BASF, EPA registration no. 271840-19)); (B1.5) Bacillus amyloliquefaciens, in particular, strain D747 (available as DOUBLE NICKEL™ from Kumiai Chemical Industry Co., Ltd. Certis, US, which holds accession no. 2 FERM BP-8234, and is disclosed in US patent no. 29, 2007, 95); (B1.6) Bacillus subtilis Y1336 (available as BIOBAC® WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under registration nos. 4764, 5454, 5096 and 5277); (B1.7) Bacillus amyloliquefaciens var. subtilis strain MBI 600 (available as SUBTILEX® from BASF SE), which hold accession no.2 NRRL B-50595, US patent no.25,061,495; (B1.8) Bacillus subtilis strain GB03 (available as KODIAK® from Bayer AG, DE); (B1.9) Bacillus subtilis var. amyloliquefaciens strain FZB24 bearing accession no.2 DSM 10271 [available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA registration n.s70127-5)] (available from Novozymes Biologicals Inc., Salem, Virginia or Syngenta Crop Protection, LLC, Greensboro, North Carolina as the fungicide TAEGRO® or TAEGRO® ECO (EPA registration no. 270127-5); (B1.10) Bacillus mycoides, isolate J, having accession no. B-30890 (available as BMJ TGAI® WG and LIFEGARD™ from Certis USA LLC, a subsidiary of Mitsui & Co.) (available as BMJ TGAI® or WG from Certis USA); (B1.11) Bacillus licheniformis, in particular strain SB3086, having accession no. 2 ATCC 55406, WO 2003 / 000051 (available as ECOGUARD® Biofungicide and GREEN RELEAF™ from Novozymes); (B1.12) a strain of sp. Paenibacillus having accession no. 2 NRRL B-50972, or accession no. 2 NRRL B-67129, and described in International Patent Publication no. 2 WO 2016 / 154297; (B1.13) Bacillus subtilis strain BU1814, (available as VELONDIS® PLUS, VELONDIS® FLEX and VELONDIS® EXTRA from BASF SE); (B1.14) Bacillus subtilis CX-9060 from Certis USA LLC, a subsidiary of q Lznnn / zznz / E / YiAi. Mitsui & Co.; (B1.15) Bacillus amyloliquefaciens strain F727 (also known as strain MBI110) (accession n.sde NRRL B-50768; WO 2014 / 028521) (STARGUS® from Marrone Bio Innovations); (B1.16) Bacillus amyloliquefaciens strain FZB42, accession no. DSM 23117 (available as RHIZOVITAL® from ABiTEP, DE); (B1.17) Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (QUARTZO® (WG) and PRESENCE® (WP) from FMC Corporation); (B1.18) Bacillus mojavensis strain R3B (NCAIM accession no. (P) B001389) (WO 2013 / 034938) from Certis USA LLC, a subsidiary of Mitsui & Co.; (B1.19) Paenibacillus polymyxa esp. plantarum (WO 2016 / 020371) from BASF SE; (B1.20) Paenibacillus epiphyticus (WO 2016 / 020371) from BASF SE; (B.1.21) Pseudomonas chlororaphis strain AFS009, bearing accession n.sde NRRL B-50897, WO 2017 / 019448 (e.g., HOWLER™ and ZIO® from AgBiome Innovations, US); (B1.22) Pseudomonas chlororaphis, in particular, strain MA342 (e.g., CEDOMON®, CERALL® and CEDRESS® by Bioagri and Koppert); (B1.23) Streptomyces lydicus strain WYEC108 (also known as Streptomyces lydicus strain WYCD108US) (ACTINO-IRON® and ACTINOVATE® from Novozymes); (B1.24) Agrobacterium radiobacterium strain K84 (e.g., GALLTROL-A® from AgBioChem, CA); (B1.25) Agrobacterium radiobacter strain K1026 (e.g., NOGALLTM from BASF SE); (B1.26) Bacillus subtilis strain KTSB (FOLIACTIVE® from Donaghys); (B1.27) Bacillus subtilis IAB / BS03 (AVIV™ from STK Bio-Ag Technologies); (B1.28) Bacillus subtilis strain Y1336 (available as BIOBAC®WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under registrations nos. 4764, 5454, 5096 and 5277); (B1.29) Bacillus amyloliquefaciens isolate B246 (e.g., AVOGREEN™ from the University of Pretoria); (B1.30) Bacillus methylotrophicus strain BAC-9912 (from the Chinese Academy of Sciences' Institute of Applied Ecology); (B1.31) Pseudomonas proradix (e.g., PRORADIX® from Sourcon Padena); (B1.32) Streptomyces griseoviridis strain K61 (also known as Streptomyces galbus strain K61) (n.(see DSM 7206) (MYCOSTOP® by Verdera; PREFENCE® by BioWorks; cf. Crop Protection 2006, 25, 468-475); (B1.33) Pseudomonas fluorescens cepa A506 (e.g., BLIGHTBAN® A506 by NuFarm); and (B2) hongos, for example: (B2.1) Coniothyrium minitans cepa CON / M / 91-8 (n.ede accessed DSM9660; e.g., CONTANS® by Bayer CropScience Biologics GmbH); (B2.2) Talaromyces flavuscepa V117b; (B2.3) Trichoderma atroviride cepa CNCM 1-1237 (e.g., ESQUIVE® WP by Agrauxine, FR); (B2.4) Gliocladium catenulatum (synonym: Clonostachys rosea f. catenulate) cepa J1446 (p. ej., PRESTOP® por Lallemand); (B2.5) Trichoderma viride cepa B35 (Pietr et al., 1993, Zesz. Nauk. AR w Szczecinie 161: 125-137); (B2.6) Metschnikowia fructicola cepa NRRL Y-30752; (B2.7) Gliocladium roseum (also known as Clonostachys rosea f.rosea), in particular, cepa 321U de Adjuvants Plus, cepa ACM941 as revealed in Xue (Efficacy of Clonostachys q Lznnn / zznz / E / YiAi rosea strain ACM941 and fungicide seed treatments for controlling the root tot complex of field pea, Can Jour Plant Sci 83(3): 519-524), cepa IK726 (Jensen, D.F., et al. “Development of a Biocontrol Active Compound for Plant Disease Control with Special Emphasis on the Near Commercial Fungal Antagonist Clonostachys rosea Strain ΊΚ726'”; Australes Plant Pathol. 2007; 36:95-101); (B2.8) Trichoderma asperellum cepa SKT-1, que posee el n.sde acceso FERM P16510 (p. ej., ECO-HOPE® de Kumiai Chemical Industry); Trichoderma asperellum T34 (ASPERELLO® de Biobest Group NV y T34 BIOCONTROL® por Biocontrol Technologies SL, ES); (B2.9) Trichoderma asperelloides JM41R (n.2de acceso NRRL B-50759) (TRICHO PLUS® de BASF SE); (B2.10) Trichoderma asperellum cepa ICC 012 (Isagro); Trichoderma atroviride cepa SC1, que posee el n.2nd accession CBS 122089, WO 2009 / 116106 and United States patent no. 28,431,120, (of Bi-PA), strain 77B (T77 of Andermatt Biocontrol), strain LU132 (e.g., SENTINEL® of Agrimm Technologies Limited), strain having accession no. NMIV08 / 002387, strain having accession no. 2 NMI V08 / 002388, strain having accession no. 2 NMI V08 / 002389, strain having accession no. 2 NMI V08 / 002390, strain having accession no. 2 ATCC 20476 (IMI 206040), strain SKT-1, having accession no. 2 FERM P-16510, patent publication JP (Kokai) 11-253151 A, strain SKT-2, having FERM accession no. 2 P-16511, patent publication JP (Kokai) 11-253151 A, strain SKT-3, having FERM accession no. (B2.11) Trichoderma harzianum strain T-22 (e.g., TRIANUM-P® from Andermatt Biocontrol or Koppert), strain DB 103 (available as TGRO® 7456 from Dagutat Biolab); (B2.12) Trichoderma virens (also known as Gliocladium virens), in particular strain GL-21 (e.g.ej., SOILGARD® by Certis, US); (B2.13) Trichoderma harzianum cepa Cepa Simb-T5 (by Simbiose Agro); (B2.14) Aspergillus flavus cepa NRRL 21882 (products known as AFLA-GUARD® by Syngenta / ChemChina); (B2.15) Chaetomium cupreum (n.2de accesso CABI 353812) (p. ej., BIOKUPRUM™ by AgriLife); (B2.16) Microsphaeropsis ochracea; (B2.17) Saccharomyces cerevisiae cepa LASO2 (de Agro-Levures et Dérivés), paredes celulares de la cepa LAS117 (CEREVISANE® de Lesaffre; ROMEO® de BASF SE), cepas CNCM n.sI-3936, CNCM η.9I-3937, CNCM η.2I-3938, CNCM η.9I-3939 (WO 2010 / 086790) de Lesaffre et Compagnie, FR; (B2.18) Trichoderma virens cepa G-41, formerly known as Gliocladium virens (n.2de acc. ATCC 20906) (e.g., ROOTSHIELD® PLUS WP and TURFSHIELD® PLUS WP de BioWorks, US); (B2.19) Gliocladium roseum cepa 321 U, which was listed in n.2 of ATCC 10406, from WF Stoneman Company LLC; (B2.20) Trichoderma hamatum, which was listed under ATCC 28012; (B2.21) Trichoderma harzianum cepa TH35 (p. ej., ROOT-PRO® by Mycontrol); (B2.22) Ampelomyces quisqualis strain AQ10, which possesses the q Lznnn / zznz / E / YiAi. CNCM accession no. I-807 (e.g., AQ 10® by IntrachemBio Italia); (B2.23) Aureobasidium pullulans having DSM accession no. 14940, strain having DSM accession no. 14941; (B2.24) Cladosporium cladosporioides strain H39, having CBS122244 accession no., U.S. patent application publication no. 2010 / 0291039 (by Stichting Dienst Landbouwkundig Onderzoek); (B2.25) Lecanicillium longisporum (formerly known as Lecanicillium lecanii and also Verticillium lecanii) strain KV01 (e.g., VERTALEC® by Koppert BV, Netherlands / Arysta); (B2.26) Penicillium vermiculatum; (B2.27) Pichia anomala strain WRL076, which has accession no. NRRL Y-30842, U.S. patent no. 7,579,183; (B2.28) Trichoderma asperellum strain kd (e.g., T-GRO by Andermatt Biocontrol); (B2.29) Trichoderma polysporum strain IMI 206039, which has accession no. IMI 206039 (e.g., BINAB® TF WP by BINAB Bio-innovation AB, Sweden); (B2.30) Trichoderma stromaticum, which has accession no.2access Ts3550 (e.g., TRICOVAB® by CEPLAC, Brazil); (B2.31) Ulocladium oudemansü strain U3, having accession no. NM 99 / 06216 (e.g., BOTRY-ZEN® by Botry-Zen Ltd, New Zealand and BOTRYSTOP® by BioWorks, Inc.); (B2.32) Vertícillium albo-atrum (formerly V. dahliaé), which has accession number WCS850, deposited at the Central Office of Fungal Cultures (e.g. DUTCH TRIG® by Tree Care Innovations); (B2.33) Verticillium chlamydosporium; (B2.34) mixtures of Trichoderma asperellum strain ICC 012 (also known as Trichoderma harzianum ICC012), having CABI CC IMI accession no. 2 392716, (B2.35) Trichoderma gamsii (formerly T. viride) strain ICC 080, having IMI accession no. 2 392151 (e.g., BIO-TAM™ by Isagro USA, Inc. and BIODERMA® by Agrobiosol de México, SA de CV); (B2.36) Phlebiopsis gigantea strain VRA1992 (ROTSTOP® C by Danstar Ferment); (B2.37) Penicillium steckii (DSM 27859; WO 2015 / 067800) by BASF SE; (B2.38) Chaetomium globosum (available as RIVADIOM® by Rivale); (B2.39) Cryptococcus flavescens, cell 3C (NRRL Y-50378); (B2.40) Dactylaria candida; (B2.41) Dilophosphora alopecuri (available as TWIST FUNGUS®); (B2.42) Fusarium oxysporum, cell Fo47 (available as FUSACLEAN® by Natural Plant Protection); (B2.43) Lecanicillium lecanii (formerly known as Verticillium lecanii) cell KV01 (available as VERTALEC® by Koppert / Arysta); (B2.44) Penicillium vermiculatum; (B2.45) Pichia anómala, cell WRL-076 (NRRL Y-30842); (B2.46) Pseudozyma flocculosa, cepa PF-A22 UL (available as SPORODEX® L by Plant Products Co., CA); (B2.47) Trichoderma gamsii (antes T viride), cepa ICC080 (IMI CC 392151 CABI) (available as BIODERMA® by AGROBIOSOL DE MEXICO, SA DE CV); Trichoderma polysporum, cepa IMI 206039 (available as BINAB TF® WP by BINAB Bio-innovation AB, Suecia); Trichoderma stromaticum (available as TRICOVAB® by Ceplac, Brazil); Tsukamurella paurometabola, cepa C-924 (available as HEBERNEM® for q Lznnn / zznz / E / YiAi. Gavac); Ulocladium oudemansii, in particular, the HRU3 strain (available as BOTRY-ZEN® by Botry-Zen Ltd, NZ); Verticillium albo-atrum (antes V. dahliae), cepa WCS850 (CBS 276.92); Trichoderma fertile (e.g., the TRICHOPLUS® product from BASF); Muscodor roseus, in particular, the A3-5 variety (n.Qde acc. NRRL 30548); mezclas de Trichoderma asperellum cepa ICC 012 y Trichoderma gamsii cepa ICC 080 (e.g., BIO-TAM™ de Isagro USA, Inc. y BIODERMA® por Agrobiosol de México, SA de CV); Simplicillium lanosoniveum. The biologically active compound may be a plant growth-promoting active compound. Such plant growth-promoting active compounds comprise (E1) bacteria selected from (E1.1) Bacillus pumilus, in particular, strain QST2808 (having accession no. NRRL B-30087) or strain GB34 (e.g., YIELD SHIELD® from Bayer CropScience, DE); (E1.2) Bacillus subtilis, in particular strain QST713 / AQ713 (having accession no. NRRL B-21661 and described in U.S. patent no. 6,060,051; available as SERENADE® OPTI or SERENADE® ASO from Bayer CropScience LP, US), strain AQ30002 (having accession no. NRRL B-50421 and described in U.S. patent application no. 213 / 330,576), strain AQ30004 (and NRRL B-50455 and described in U.S. patent application no. 213 / 330,576), strain MBI 600 (e.g., SUBTILEX® from BASF SE); (E1.3) Sinorhizobium meliloticepa NRG-185-1 (NITRAGIN® GOLD from Bayer CropScience); (E1.4) Bacillus subtilis strain BU1814, (available as TEQUALIS® from BASF SE); (E1.5) Bacillus subtilis strain rm303 (RHIZOMAX® from Biofilm Crop Protection); (E1.6) Bacillus amyloliquefaciens strain pm414 (LOLI-PEPTA®from Biofilm Crop Protection), strain SB3281 (ATCC η.2PTA-7542; WO 2017 / 205258), strain TJ1000 (available as QUIKROOTS® from Novozymes strain93), strain SB3281 strain FZB42 (e.g., RHIZOVITAL® by ABÍTEP, DE), strain BS27 (NRRL accession no. B-5015); (E1.7) Bacillus mycoides strain BT155 (NRRL η.2B-50921), strain EE118 (NRRL η.2B-50918), strain EE141 (NRRLn.2B-50916),strainBT46-3(NRRLn.2B-5092), member of Bacillus (NRRLn.2B-50921). family EE128 (NRRL η.2B-50917) or family member EE349 (NRRL η.2B-50928), (E1.9) Bacillus thuringiensis BT013A (NRRL η.2B-50924) also known as Bacillus thuringiensis (NRRL η.2B-50924) Bacillus firmus, in particular, strain CNCM 1-1582 (e.g., VOTIVO® from BASF SE); (E1.11) a mixture of Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (available as QUARTZO® (WG), PRESENCE® (WP) from FMC Corporation); (E1.12) Bacillus cereus, in particular, cepa BP01 (ATCC 55675; p. ej., MEPICHLOR® de Arysta Lifescience, US); (E1.13) Bradyrhizobium japonicum (p. ej., OPTIMIZE® de Novozymes); (E1.14) Mesorhizobium cicer (e.g., NODULATOR® de BASF SE); (E1.15) Rhizobium leguminosarium q Lznnn / zznz / E / YiAi biovarviciae (e.g., NODULATOR® de BASF SE); (E1.16) Delftia acidovorans, in particular, the cepa RAY209 (e.g., BIOBOOST® by Brett Young Seeds); (E1.17) esp. Lactobacillus (e.g., LACTOPLANT® de LactoPAFI); (E1.18) Paenibacillus polymyxa, in particular, the type AC-1 (e.g., TOPSEED® de Green Biotech Company Ltd.); (E1.19) Pseudomonas proradix (p. ej., PRORADIX® de Sourcon Padena); (E1.20) Azospirillum brasilense (p. ej., VIGOR® de KALO, Inc.); (E1.21) Azospirillum lipoferum (e.g., VERTEX-IF™ de TerraMax, Inc.); (E1.22) a mixture of Azotobacter vinelandii and Clostridium pasteurianum (available as INVIGORATE® from Agrinos); (E1.23) Pseudomonas aeruginosa, in particular, strain PN1; (E1.24) Rhizobium leguminosarum, in particular e.g. viceaecepa Z25 (no.2de access CECT 4585); (E1.25) Azorhizobium caulinodans, in particular, strain ZB-SK-5; (E1.26) Azotobacter chroococcum, in particular, strain H23; (E1.27) Azotobacter vinelandii, in particular, strain ATCC 12837; (E1.28) Bacillus siamensis, in particular, strain KCTC 13613T; (E1.29) Bacillus tequilensis, in particular, strain NII-0943; (E1.30) Serratia marcescens, in particular, the strain SRM (accession no.MTCC 8708); (E1.31) esp. Thiobacillus (e.g., CROPAID® by Cropaid Ltd UK); (E1.22) Bacillus megaterium, in particular, strain NRRL B-67357 (see WO2018 / 129016); Bacillus psychrosaccharolyticus strain PTA123720 (see WO2018 / 128986); and (E2) fungi selected from (E21) Purpureocillium lilacinum (formerly known as Paecilomyces lilacinus) cepa 251 (AGAL 89 / 030550; e.g., BIOACT® de Bayer CropScience Biologics GmbH); (E2.2) Penicillium bllaii cepa ATCC 22348 (e.g., JUMPSTART® de Acceleron BioAg), (E2.3) Talaromyces flavus cepa V117b; (E2.4) Trichoderma atroviride cepa CNCM 1-1237 (e.g., ESQUIVE® WP de Agrauxine, FR), (E2.5) Trichoderma viride, p. ej., cepa B35 (Pietr et al., 1993, Zesz. Nauk. AR w Szczecinie 161: 125-137); (E2.6) Trichoderma atroviride cepa LC52 (also known as Trichoderma atroviride cepa LU132; e.g., SENTINEL® de Agrimm Technologies Limited); (E2.7) Trichoderma atroviride cepa SC1 described in the Solicitud Internacional n.sPCT / IT2008 / 000196); (E2.8) Trichoderma asperellum cepa kd (p. ej., T-GRO®de Andermatt Biocontrol); (E2.9) Trichoderma asperellum cepa Eco-T (Plant Health Products, ZA); (E2.10) Trichoderma harzianum cepa T-22 (e.g., TRIANUM-P® de Andermatt Biocontrol o Koppert); (E2.11) Myrothecium verrucaria cepa AARC-0255 (e.g., DITERA™ de Valent Biosciences); (E2.12) Penicillium bilaii cepa ATCC 20851; (E2.13) Pythium oligandrum cepa M1 (ATCC 38472; p. ej., POLYVERSUM® de Bioprepraty, CZ); (E2.14) Trichoderma virens cepa GL21 (p. ej., SOILGARD®de Certis, EE. UU.); (E2.15) Verticillium albo-atrum (antes V. dahliae) cepa WCS850 (CBS 276.92; p. ej., DUTCH TRIG® de Tree Care Innovations); (E2.16) Trichoderma atroviride, in particular, cepa n.sV08 / 002387, cepa NMI n.sV08 / 002388, cepa η.2NMI n.2q Lznnn / zznz / E / YiAi. V08 / 002389, strain n.sNMI n.sV08 / 002390; (E2.17) Trichoderma harzianum strain ITEM 908, strain TSTh20, strain 1295-22; (E2.18) Pythium oligandrum strain DV74; (E2.19) Rhizopogon amylopogon (e.g., comprised in MYCO-SOL® from Helena Chemical Company); (E2.20) Rhizopogon fulvigleba (e.g., comprised in MYCO-SOL® from Helena Chemical Company); (E2.21) Trichoderma koningir, (E2.22) Glomus aggregatum; (E2.23) Glomus clarum; (E2.24) Glomus deserticola; (E2.25) Glomus etunicatum; (E2.26) Intraradical glomus; (E2.27) Glomus monosporum; (E2.28) Glomus mosseae; (E2.29) Bicolor laceria, (E2.30) Rhizopogon luteolus·, (E2.31) Rhizopogon tinctorus; (E2.32) Rhizopogon villosulus; (E2.33) Scleroderma strain; (E2.34) Suillus granulatus; (E2.35) Suillus punctatapies; (E2.36) Trichoderma virens strain GI-3; (E2.37) Pseudozyma aphidis (e.g., from Yissum Research Development Company of the Hebrew University of Jerusalem). Biologically active compounds for plant growth promotion also include (F) bacteria and fungi that can be added as “inoculants” to plants or parts of plants or plant organs and that, by virtue of their particular properties, promote plant growth and health. Examples are: Agrobacterium spp., Azorhizobium caulinodans, Azospirillum spp., Azotobacter spp., Bradyrhizobium spp., Burkholderia spp., in particular Burkholderia cepacia (formerly known as Pseudomonas cepacia), Gigaspora spp., or Gigaspora monosporum, Glomus spp., Lacearia spp., Lactobacillus buchneri, Paraglomus spp., Pisolithus tinctorus, Pseudomonas spp., Rhizoblum spp., in particular Rhizobium trifolü, Rhizopogon spp., Scleroderma spp., Suillus spp., and Streptomyces spp.; and plant extracts and products formed by microorganisms that include proteins and secondary metabolites that can be used as active biological control compounds, such as Allium sativum, Artemisia absinthium, azadirachtin, BIOKEEPER® WP, Cassia nigricans, Celastrus angulatus, Chenopodium anthelminticum, chitin, ARMOUR-ZEN®, Dryopteris filix-mas, Equisetum arvense, FORTUNE AZA®, FUNGASTOP®, HEADS UP® (Chenopodium quinoa saponin extract), Pyrethrum / Pyretrins, Quassia amara, Quercus, Quillaja, Regalía, “REQUIEM® insecticide”, rotenone, riania / ryanodine, Symphytum officinale, Tanacetum vulgare, thymol, TRIACT® 70, TRICON®, Tropaeulum majus, Urtica dioica, VERATRIN®, Viscum album, extract of Brassicaceae, in particular oilseed rapeseed powder or mustard powder. Plant growth-promoting biological compounds may also include one or more lipochitooligosaccharides (LCOs), chytooligosaccharides (COs), and / or chitinous compounds. LCOs, sometimes called symbiotic nodulation signals (Nods), Nod factors, or Myc factors, consist of a backbone oligosaccharide chain of β-I,4-N-acetyl-D-glucosamine residues (“GIcNAc”) with a fatty acyl chain attached to a condensed N-terminal end. As understood in the art, LCOs differ in the number of GIcNAc residues in the backbone, in the length and degree of saturation of the fatty acyl chain, and in the substitutions of reducing and non-reducing sugar residues. See, p. e.g., Denarie et al., Ann. Rev. Biochem. 65:503 (1996); Díaz et al., Mol. Plant-Microbe Interactions 13:268 (2000); Hungría et al., Solí Biol. Biochem. 29:819 (1997); Hamel et al., Planta 232:787 (2010); and Prome et al., Puré & Appl.Chem. 70(1):55 (1998), whose contents and disclosures are incorporated in this document as a reference. LCOs can be synthetic or obtained from any suitable source. See, e.g., documents WO 2005 / 063784, WO 2007 / 117500, and WO 2008 / 071674, the contents and disclosures of which are incorporated herein by reference. In some respects, a synthetic LCO may have the basic structure of a natural LCO but contain one or more modifications or substitutions, such as those described in Spaink, Crit. Rev. Plant Sci. 54:257 (2000). LCOs and precursors for LCO construction (e.g., CO, which may be useful as a biologically active ingredient) can be synthesized by genetically modified organisms. See, e.g., Samain et al., Carbohydrate Res. 302:35 (1997); Cottaz et al., Meth. Eng. 7(4):311 (2005); and Samain et al., J. Biotechnol. 72:33 (1999) (e.g., Figure 1 therein, which shows CO structures that can be recombinantly manufactured in E.coli that harbor different combinations of nodBCHL genes), whose contents and disclosures are incorporated in this document as a reference. Liquefied microbial cells (and their derivatives) can be included in or used in compositions in various forms of purity and can be used alone or in the form of an LCO-producing bacterial or fungal culture. For example, OPTIMIZE® [commercially available from Monsanto Company (St. Louis, MO)] contains an LCO-producing culture of Bradyrhizobium japonicum. Methods for providing substantially pure LCO include removing the microbial cells from a mixture of LCO and the microbe, or further isolating and purifying the LCO molecules through phase separation of the LCO solvent, followed by HPLC chromatography as described, for example, in U.S. Patent No. 5,549,718. Purification can be enhanced by repeated HPLC, and the purified LCO molecules can be lyophilized for long-term storage. In one embodiment, the biological control active compound is selected from Bacillus subtilis strain QST713 / AQ713; a strain of esp. Paenibacillus bearing accession no. NRRL B-50972, or accession no. eNRRL B-67129, Bacillus pumilus strain BU F-33; Bacillus subtilis q Lznnn / zznz / E / YiAi strain BU1814; esp. Bacillus D747; Bacillus subtilis var.amyloliquefaciens strain FZB24; Bacillus mojavensis strain R3B; Bacillus subtilis CX-9060, Bacillus pumilus strain QST2808, Coniothyrium minitans strain CON / M / 91 -8; Talaromyces flavus strain V117b; Trichoderma atroviride strain CNCM 1-1237; Gliocladium catenulatum strain J1446; Trichoderma viride strain B35; Metschnikowia fructicola strain NRRL Y-30752; Gliocladium roseum strain 321U, strain ACM941, strain IK726; Trichoderma asperellumcepa SKT-1; Trichoderma asperellum T34; Trichoderma asperellumcepa T34; Trichoderma asperelloides JM41R; Sinorhizobium meliloticepa NRG-185-1, Purpureocillium lilacinum strain 251, Penicillium bilaii, strain ATCC 22348, Trichoderma atroviride strain LC52; Trichoderma atroviride strain SC1; Trichoderma asperellum strain kd; Trichoderma asperellum strain Eco-T; Trichoderma harzianum strain T-22; Myrothecium verrucaria strain AARC-0255; Penicillium bilaii strain ATCC 20851. In another embodiment, the active biological compound is selected from Bacillus subtilis strain QST713 / AQ713; a strain of esp. Paenibacillus that has accession no. NRRL B-50972, or accession no.sNRRL B-67129, Bacillus pumilus strain QST2808, Coniothyrium minitans strain CON / M / 91-8; Trichoderma atroviride strain CNCM 1-1237; Gliocladium catenulatum strain J1446; Trichoderma viride strain B35, Metschnikowia fructicola strain NRRL Y-30752; Sinorhizobium meliloti strain N RG-185-1, Purpureocillium lilacinum strain 251, Penicillium bilaii strain ATCC 22348. The biologically active compounds comprise bacteria such as spore-forming bacteria, root-colonizing bacteria, and bacteria that act as biological fungicides, insecticides, acaricides, or nematicides, or as plant growth promoters. In a further embodiment of the invention, the combinations of active compounds, according to the invention, comprise (a) Bacillus spp. strain NRRL B-67746 or a plant growth-promoting mutant of this strain and at least one compound, and (b) at least one compound selected from the following groups of bacteria that are or can be used as biologically active compounds: Bacillus amyloliquefaciens, cepa FZB42 (DSM 231179), or Bacillus cereus, in particular B. cereus cepa CNCM 1-1562 or Bacillus firmus cepa 1-1582 (sde n. acc. CNCM 1-1582) or Bacilluspumilus, in particular, cepa GB34 (sde n. acc. ATCC 700814) y cepa QST2808 (sde n. accessed NRRL B-30087), or Bacillus subtilis, in particular, the cepa GB03 (sde n. accessed ATCC SD-1397), or Bacillus subtilis cepa QST713 (sde n. accessed NRRL B-21661) or Bacillus subtilis cepa OST30002 (n.2de accessed NRRL B-50421) Bacillus thuringiensis, en particular B. thuringiensis subespecies israelensis (serovar H-14), cepa AM65-52 (n.2de acc. ATCC 1276), or B. thuringiensis subesp. aizawai, in particular, the cepa ABTS-1857 (SD-1372), or B. subesp. thuringiensis kurstaki cepa q Lznnn / zznz / E / YiAi HD-1, or B. subesp. thuringiensis tenebrionis cepa NB 176 (SD-5428), Pasteuria penetraos, esp. Pastearía (Rotylenchulus reniformis nemátodo)-PR3 (n.sde accesso ATCC SD-5834), Streptomyces microflavus cepa AQ6121 (NRRL B-50550), Streptomyces galbus cepa AQ6047 (n.sde accesso NRRL 30232). 1) Fungi and yeasts that are or can be used as biologically active compounds: Beauveria bassiana, in particular strain ATCC 74040, Coniothyrium minitans, in particular strain CON / M / 91-8 (accession no. DSM-9660), Lecanicillium spp., in particular strain HRO LEC 12, Lecanicillium lecanii (formerly known as Verticillium lecanii), in particular strain KV01, Metarhizium anisopliae, in particular strain F52 (DSM3884 / ATCC 90448), Metschnikowia fructicola, in particular strain NRRL Y-30752, Paecilomyces fumosorosea (new: Isaria fumosorosea), in particular strain IFPC 200613 or strain Apopka 97 (accession no. ATCC 20874), Paecilomyces lilacinus, in particular P. lilacinus strain 251 (AGAL 89 / 030550), Talaromyces flavus, in particular strain V117b, Trichoderma atroviríde, in particular strain SC1 (accession no. CBS 122089), Trichoderma harzianum, in particular T. harzianum rifai T39 (accession no. 5 CNCM I-952). 2) viruses that are used or can be used as biologically active compounds: granulosis virus (GV) Adoxophyes orana (summer fruit tortrix), granulosis virus (GV) Cydia pomonella (moth), nuclear polyhedrosis virus (NPV) Helicoverpa armigera (cotton caterpillar), mNPV Spodoptera exigua (beet armyworm), mNPV Spodoptera frugiperda (autumn armyworm), NPV Spodoptera littoralis (African cotton leafworm). 3) Bacteria and fungi that are added as “inoculants” to plants or parts of plants or plant organs and that, by virtue of their particular properties, promote plant growth and health: Esp. Agrobacterium, Azorhizobium caulinodans, esp. Azospirillum, esp. Azotobacter, esp. Bradyrhizobium, esp. Burkholderia, in particular Burkholderia cepacia (formerly known as Pseudomonas cepacia), esp. Gigaspora, or Gigaspora monosporum, Gesp. lomus, esp. Lacearia, Lactobacillus buchneri, esp. Paraglomus, Pisolithus tinctorus, esp. Pseudomonas, esp. Rhizobium, in particular Rhizobium trifolii, esp. Rhizopogon, esp. Scleroderma, esp. Suillus, esp. Streptomyces. 4) Plant extracts, products made from plant extracts and products formed by microorganisms, including proteins and secondary metabolites that are used or can be used as biologically active compounds: q Lznnn / zznz / E / YiAi Allium sativum, Artemisia absinthium, azadirachtin, BIOKEEPER® WP, Cassia nigricans, Celastrus angulatus, Chenopodium anthelminticum, chitin, ARMOUR-ZEN®, Dryopteris filix-mas, Equisetum arvense, FORTUNE AZA®, FUNGASTOP®, HEADS UP® (Chenopodium quinoa saponin extract), pyrethrum / pyrethrins, Quassia amara, Quercus, Quillaja, Regalía, “REQUIEM® insecticide”, rotenone, riania / ryanodine, Symphytum officinale, Tanacetum vulgare, thymol, TRIACT® 70, TRICON®, Tropaeulum majus, Urtica dioica, Veratrin, Viscum album, Brassicaceae extract, in particular rapeseed powder or mustard powder, as well as bioinsecticidal / acaricidal active substances obtained from olive oil, in particular unsaturated fatty / carboxylic acids having carbon chain lengths of C16-C20 as active ingredients, such as those contained in the product with the trade name FLIPPER®. Protector as a mixture partner (b) Compounds (a) can be combined with protectants such as benoxacor, cloquintocet (mexyl), ciometrinil, cyprosulfamide, dichlormide, fenchlorazole (-ethyl), fenchlorim, flurazole, fluxofenim, furylazole, isoxadifen (-ethyl), mefenpyr (-diethyl), italic anhydride, oxabetrinil, 2-methoxy-N-({4[(methylcarbamoyl)amino]phenyl}sulfonyl)benzamide (CAS 129531-12-0), 4-(dichloroacetyl)-1-oxa-4azaespiro[4.5]decane (CAS 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-1,3-oxazolidine (CAS 52836-31-4). Ratio of Bacillus species (CFU) with chemical fungicide or chemical pesticide The compound combinations according to the invention may comprise one, two, or even more compounds (b). Preferably, the compound combinations according to the invention comprise one or two compounds (b). In one embodiment, all compounds (b) are fungicides. However, if two or more compounds (b) are present, they may be selected from different groups (1) to (15). For example, if one compound (b) is selected from group (1), the additional compounds (b) may be selected from groups (2) to (15). According to the invention, the term “combination” refers to various combinations of (a) and (b), for example, in a single “ready-mix” form, in a combined spray mixture composed of separate formulations of the individual active compounds, such as a “tank mix,” and in a combined use of the individual active ingredients when applied sequentially, i.e., one after the other within a reasonably short period, such as a few hours or days. Preferably, the order of application of compounds (a) and (b) is not essential to the operation of the present invention. If more than one compound (b), for example, 2 or 3, are present in a combination according to the invention, the weight ratio refers to the total amount of compound (b), i.e., the sum q Lznnn / zznz / E / YiAi of the amount of each compound (b) present in the combination. This applies mutatis mutandis if more than one compound (a) is present, for example, 2 or 3. The compounds (b) may be of the same type, e.g., two or more fungicides, or a combination of different types, e.g., a fungicide and a biological compound or a pesticide. If more than one compound (b), for example, two or three, is present in the combinations according to the invention, the individual compounds (b) may be present in a wide range of effective weight ratios. If, for example, two compounds (b), hereinafter referred to as compounds (B1) and (B2), are present, the effective weight ratio of B1:B2 may vary, for example, in a range of 100:1 to 1:100, preferably in a weight ratio of 50:1 to 1:50, and more preferably in a weight ratio of 20:1 to 1:20. The additional B1:B2 ratios that may be used according to the present invention, in increasing preference in the given order, are as follows: 95:1 to 1:95, 90:1 to 1:90, 85:1 to 1:85, 80:1 to 1:80, 75:1 to 1:75, 70:1 to 1:70, 65:1 to 1:65, 60:1 to 1:60, 55:1 to 1:55, 50:1 to 1:50, 45:1 to 1:45, 40:1 to 1:40, 35:1 to 1:35, 30:1 to 1:30, 25:1 to 1:25, 15:1 to 1:15, 10:1 to 1:10, 5:1 to 1:5. 4:1 to 1:4, 3:1 to 1:3, 2:1 to 1:2.The additional B1 :B2 ratios that can be used according to the present invention are as follows: 95:1 to 1:1,90:1 to 1:1,85:1 to 1:1,80:1 to 1:1,75:1 to 1:1,70:1 to 1:1,65:1 to 1:1, 60:1 to 1:1,55:1 to 1:1,50:1 to 1:1,45:1 to 1:1,40:1 to 1:1,35:1 to 1:1,30:1 to 1:1,25:1 to 1:1,20:1 to 1:1,15:1 to 1:1, 10:1 to 1:1,5:1 to 1:1,4:1 to 1:1,3:1 to 1:1,2:1 to 1:1. Ratios other than weight ratios can be provided for active compounds that are not chemical fungicides or pesticides, such as active microbial compounds. The colony-forming unit (CFU) is a measure of viable microbial cells, particularly fungal and bacterial cells. The ratio of the Bacillus strain to a chemical fungicide or pesticide is given in terms of CFU:g of bacteria. Typically, the ratio of the Bacillus strain as described herein to a chemical fungicide or pesticide is 10¹⁸ CFU:g to 10⁴ CFU:g. In one embodiment, the ratio of the Bacillus strain to a chemical fungicide or pesticide is 10¹⁷ CFU:g to 10⁵ CFU:g. In another embodiment, the Bacillus strain... Bacillus as described herein for a chemical fungicide or pesticide is 1015CFU:1 g to 108CFU:1 g. In yet another embodiment, the strain of the sp.The Bacillus strain as described herein for a chemical fungicide or pesticide is from 10¹³ CFU:1 g to 10⁹ CFU:1 g. In another embodiment, the Bacillus strain as described herein for a chemical fungicide or pesticide is from 10¹³ CFU:1 g to 10¹ CFU:1 g. In one embodiment, these relationships specifically refer to the relationships between the Bacillus strain of NRRL B-67746 and a chemical fungicide or pesticide. Ratio of Bacillus species (CFU) to a biologically active compound (CFU) If a biologically active compound (b) is a bacterium or a fungus, the amount of that biologically active compound can be measured in CFU. The ratio of the Bacillus strain to a biologically active compound is typically in the range of 1000:1 CFU of compound (a):CFU of compound (b) to 1:1000 CFU of compound (a):CFU of compound (b). In another embodiment, the ratio is 100:1 CFU of compound (a):CFU of compound (b) to 1:100 CFU of compound (a):CFU of compound (b). In yet another embodiment, the ratio is 25:1 to 1:25, as well as 10:1 to 1:10. In yet another embodiment, the ratio is 4:1 to 1:4. In one embodiment, these ratios specifically refer to the ratios between the Bacillus strain of NRRL B-67746 and a bacterium or a fungus. Ratio of Bacillus species (CFU) to a biologically active compound (PFU) If a biologically active compound is a virus, the amount of that biologically active compound can be measured in PFU (plaque-forming units). The ratio of the Bacillus strain to a biologically active compound is typically in the range of 1000:1 CFU of compound (a):PFU of compound (b) to 1:1000 CFU of compound (a):PFU of compound (b). In another embodiment, the ratio is 100:1 CFU of compound (a):PFU of compound (b) to 1:100 CFU of compound (a):PFU of compound (b). In yet another embodiment, the ratio is 25:1 to 1:25, as well as 10:1 to 1:10. In yet another embodiment, the ratio is 4:1 to 1:4. In one embodiment, these ratios specifically refer to the ratios between the Bacillus strain of NRRL B-67746 and a virus. In another embodiment, an active compound combination comprises (a) the Bacillus NRRL B-67746 strain, and (b) an active compound selected from the group consisting of metalaxyl, prothioconazole, fluoxastrobin, clothianidin, Bacillus firmus 1-1582, imidacloprid, Bacillus megaterium NRRL B-67357 and an LCO. In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain and metalaxyl. In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain and prothioconazole. In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain and fluoxastrobin. q Lznnn / zznz / E / YiAi In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain and clothianidin. In yet another embodiment, a combination of active compound comprises the strain of the species Bacillus NRRL B-67746 and Bacillus firmus 1-1582. In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain and imidacloprid. In yet another embodiment, a combination of active compound comprises the strain of the species Bacillus NRRL B-67746 and Bacillus megaterium NRRL B-67357. In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain and an LCO. In another embodiment, an active compound combination comprises (a) the Bacillus NRRL B-67746 strain, and (b) an active compound selected from the group consisting of thiodicarb, imidacloprid, carbendazim, thiram, and Bradyrhizobium japonicum. In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain, thiodicarb, and imidacloprid. In yet another embodiment, an active compound combination comprises the Bacillus NRRL B-67746 strain, carbendazim, and thiram. In yet another embodiment, a combination of active compound comprises the strain of the species Bacillus NRRL B-67746 and Bradyrhizobium japonicum. Certain combinations of active compounds presented above may have a synergistic effect in certain compound (a) to compound (b) ratios. A synergistic effect of active ingredients occurs when the activity of the combinations of active ingredients exceeds the total activity of the individual active ingredients when applied separately. The expected activity for a given combination of two active ingredients can be calculated as follows (cf. Colby, SR, “Calculating Synergistic and Antagonistic Responses of Herbicide Combinations,” Weeds 1967, 15, 20-22): Yeah X is the efficacy when active ingredient A is applied at an application rate of m ppm (og / ha), Y is the efficacy when active ingredient B is applied at an application rate of n ppm (og / ha), E is the efficacy when active ingredients A and B are applied at application rates of myn ppm (og / ha), respectively, and then q Lznnn / zznz / E / YiAi If the actual activity exceeds the calculated value, then the activity of the combination is superadditive, meaning there is a synergistic effect. In this case, the observed efficacy must be greater than the expected efficacy value (E) calculated from the formula mentioned. For example, the formula and analysis can be applied to an evaluation of plant growth promotion. Such a trial is evaluated several days after application to the plants. 100% means the weight of the plant that corresponds to that of the untreated control plant. Efficacy in this case means the additional percentage of plant weight compared to that of the untreated control. For example, a treatment that resulted in a plant weight that was 120% compared to that of the untreated control plant would have an efficacy of 20%. If the plant growth-promoting effect of the combination (i.e., the observed efficacy for the percentage of shoot weight of plants treated with the combination) exceeds the calculated value, then the activity of the combination is superadditive, meaning there is a synergistic effect. The formula and analysis can also be used to evaluate synergy in disease or pest control trials. The degree of efficacy is indicated as a percentage. 0% means efficacy corresponding to control, while 100% efficacy means no disease is observed. If the actual insecticidal or fungicidal activity exceeds the calculated value, then the activity of the combination is superadditive, meaning there is a synergistic effect. In this case, the observed efficacy must be greater than the expected efficacy (E) calculated using the formula mentioned. Another way to demonstrate a synergistic effect is the Tammes method (cf. “Isoboles, A Graphic Representation of Synergism in Pesticides”, in Neth. J. Plant Path., 1964, 70, 73-80). All plants and parts of plants can be treated according to the invention. In the present context, "plants" means all plants and plant populations, such as desired and undesired wild plants or cultivated plants (including naturally occurring plants). Cultivated plants may be plants obtained by traditional breeding and optimization methods or by biotechnological and recombinant methods or combinations of these methods, including transgenic plants and plant varieties that may or may not be protected by Plant Breeders' Rights. "Parts of a plant" means all aerial and subterranean parts and organs of plants, such as shoots, leaves, flowers, and roots; examples of which include leaves, needles, stems, shoots, flowers, fruiting bodies, fruits, and seeds, as well as roots, tubers, and rhizomes.Plant parts also include growing material and vegetative and generative propagation material, for example, cuttings, tubers, rhizomes, slips and seeds. As mentioned above, all plants and their parts can be treated according to the invention. In a preferred embodiment, the invention treats plant species and plant varieties, and their parts, that grow in the wild or are obtained by traditional methods of biological reproduction such as hybridization or protoplast fusion. In another preferred embodiment, the invention treats transgenic plants and plant varieties obtained by recombinant methods, if applicable in combination with traditional methods (genetically modified organisms), and their parts. The terms “parts” or “plant parts” have been explained above. Plants of the plant varieties that are commercially available or in use are, in each case, preferably treated according to the invention.Plant varieties are defined as plants with novel traits that have been bred through traditional reproduction, mutagenesis, or recombinant DNA techniques. They can take the form of varieties, breeds, biotypes, and genotypes. The treatment of plants and plant parts with the compositions according to the invention is carried out directly or by acting on the environment, habitat, or storage space using conventional treatment methods, for example, by immersion, spraying, atomizing, misting, evaporating, dusting, fogging, dispersing, foaming, painting, spreading, injecting, soaking, drip irrigation, and, in the case of propagation material, particularly seeds, also by dry seed treatment, wet seed treatment, suspension treatment, scaling, coating with one or more layers, and similar methods. Furthermore, the active substances can be applied by ultra-low volume methods or by injecting the active substance preparation or the active substance itself into the soil. The preferred plants are those from the group of useful plants, ornamental plants, lawns, general-purpose trees used as ornamentals in the public and domestic sectors, and forest trees. Forest trees include trees intended for the production of timber, pulp, paper, and products made from tree parts. The expression “useful plants”, as used in the present context, refers to cultivated plants that are used as food, feed, ornamental plants, fuels or for industrial purposes. q Lznnn / zznz / E / YiAi Useful plants that can be treated and / or improved with the compositions and methods of the present invention include, for example, the following types of plants: turfgrass, vines, cereals, for example wheat, barley, rye, triticale, oats, rice, corn and millet / sorghum; beets, for example sugar beets and fodder beets; fruits, for example pome fruits, stone fruits and soft fruits, for example apples, pears, plums, peaches, almonds, cherries and berries, for example strawberries, raspberries, blackberries; pulses, for example beans, lentils, peas and soybeans; oilseed crops, for example rapeseed, mustard, poppies, olives, sunflowers, coconuts, oil palm, castor beans, cocoa and peanuts; cucurbits, for example pumpkin / zucchini, cucumbers and melons; Fiber plants, for example cotton, flax, hemp and jute; citrus fruits, for example oranges, lemons, grapefruits and tangerines; vegetables, for example spinach, lettuce, asparagus, cabbage, carrots, Allium spp.For example, onions, garlic, tomatoes, potatoes and peppers; laurels, for example, avocado, Cinnamomum, camphor, or plants such as tobacco, tree nuts, coffee, coca, eggplant, sugar cane, tea, pepper, vines, hops, bananas, fodder such as alfalfa, clover, forage sorghum, latex plants and ornamentals, for example, flowers, shrubs, deciduous trees and conifers. The following plants are considered to be particularly suitable target crops for applying compositions and methods of the present invention: cotton, eggplant, turf, pome fruits, stone fruits, soft fruits, maize, wheat, barley, cucumber, tobacco, vine, rice, cereals, pear, beans, soybean, rapeseed, tomato, pepper, melon, cabbage, potato, and apple. The present invention can also be applied to any type of lawn, including cool-season and warm-season lawns. Examples of cool-season turfgrasses are bluegrasses (Poa spp.), such as Kentucky bluegrass (Poa pratensis L.), rough bluegrass (Poa trivialis L.), Canada bluegrass (Poa compressa L.), annual bluegrass (Poa annua L.), upland bluegrass (Poa glaucantha Gaudin), woodland bluegrass (Poa nemoralis L.), and bulbous bluegrass (Poa bulbosa L.); creeping bentgrasses (Agrostis spp.), such as creeping bentgrass (Agrostis palustris Huds.), colonial bentgrass (Agrostis tenuis Sibth.), velvety bentgrass (Agrostis canina L.), and southern German mixed bentgrass (Agrostis spp., including Agrostis tenuis Sibth., Agrostis canina L., and Agrostis palustris Huds.); and quila grass (Agrostis alba L.), fescues (Festuca spp.), such as red fescue (Festuca rubra L. spp.rubra), creeping festuca (Festuca rubra L), chewing festuca (Festuca rubra commutata Gaud.), ovine festuca (Festuca ovina L. ), hard festuca (Festuca longifolia Thuill.), capillary festuca (Festucu capillata Lam.), tall festuca (Festuca arundinacea Schreb.) and festuca of the meadows (Festuca elanorL);. q Lznnn / zznz / E / YiAi radish {Lolium spp.), such as annual radish {Lolium multiflorum Lam.), perennial radish (Lolium perenne L.) and Italian radish (Lolium multiflorum Lam.); and wheatgrasses (Agropyron spp.), such as orchard grass (Agropyron cristatum (L.) Gaertn.), crested wheatgrass (Agropyron desertorum (Fisch.) Schult.) and western agropyrograss (Agropyron smithii Rydb.); Other examples of cool-season turfgrasses are beach grass (Ammophila breviligulata Fern.), brome smooth grass (Bromus inermis Leyss.), cattails such as fleabane (Phleum pratense L.), sand cattail (Phleum subulatum L.), orchard grass (Dactylis glomerata L.), weeping beechgrass (Puccinellia distans (L.) Parí.), and crested dogtail (Cynosurus cristatus L.). Examples of warm-season grasses are Bermuda grass {Cynodon spp. LC Rich), Zoysia grass (Zoysia spp. Willd.), St. Augustine grass (Stenotaphrum secundatum\Na\t Kuntze), centipede grass (Eremochloa ophiuroides Munro Hack.), carpet grass (Axonopus affinis Chase), Bahia grass {Paspalumnotatum Flugge), Kikuyu grass {Pennisetum clandestinum Hochst. ex Chiov.), buffalo grass {Buchloe dactyloids (Nutt.) Engelm.), blue grass {Bouteloua gracilis (HBK) Lag. ex Griffiths), bay grass {Paspalum vaginatum Swartz) and grass {Bouteloua curtipendula (Michx. Torr.) Cool season grasses are generally preferred for use according to the invention. Bluegrass, bank grass, quila grass, fescue, and ryegrass are especially preferred. Bentgrass is particularly preferred. In certain aspects, the compositions of the present invention are applied to the seed at approximately 1 x 10⁵ to approximately 1 x 10⁸ colony-forming units (CFU) of Bacillus spp. NRRL B-67746 or a plant growth-promoting mutant strain derived from it per seed, depending on the seed size. For example, in the case of a corn seed, the application rate is approximately 1 x 10⁶ CFU / seed to approximately 1 x 10⁷ CFU / seed, and in the case of soybeans, the application rate is approximately 1 x 10⁵ CFU / seed to approximately 2 x 10⁶ CFU / seed. When used as a soil treatment, the bacterial compositions and spore-forming cells of the present invention can be applied as a soil drench, applied to seedlings, injected and / or applied in the furrow, or mixed with irrigation water. The application rate for soil drench treatments, which can be applied at planting, during or after sowing, or after transplanting and at any stage of plant growth, is approximately 1 x 10¹³ to approximately 1 x 10¹⁶ colony-forming units (CFU) of Bacillus spp. NRRL B-67746 or a mutant strain of plant growth derived from it per hectare. In other respects, the compositions of the present invention are applied at approximately 1 x 10¹⁴ to approximately 1 x 10¹⁵ colony-forming units (CFU) of Bacillus spp. N, which promotes plant growth.RRL B-67746 or a plant growth mutant strain derived therefrom per hectare. In even other aspects, the compositions of the present invention are applied in approximately 1 x 10¹⁴ to approximately 5 x 10¹⁴ colony-forming units (CFU) of Bacillus spp. that stimulate plant growth. RRL B-67746 or a plant growth mutant strain derived therefrom per hectare. The application rate for foliar applications, such as lawn applications, is the same as that indicated above for soil treatment. INFORMATION ABOUT THE DEPOSIT A sample of the Bacillus spp. strain of the invention was deposited in the Agricultural Research Service Culture Collection located at the National Center for Agricultural Utilization Research, Agricultural Research Service, U.S. Department of Agriculture, 1815 North University Street, Peoria, Illinois 61604, USA, pursuant to the Treaty of Budapest on Thursday, February 14, 2019, and has been assigned the following deposit designation: NRRL B-67746. All strains described in this document and having an accession number with the prefix NRRL were deposited in the respective depository institution described above, in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These strains were deposited under conditions that ensure access to the culture will be available during the period of this patent application to a party determined by the Commissioner of Patents and Trademarks to be entitled to it under 37 CFR § 1.14 and 35 USC § 122. The deposit is available as required by foreign patent laws in the countries where counterparties to the application in question or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the invention in question in derogation of patent rights granted by government action. The following examples are given for illustrative purposes only and are not intended to limit the present invention. EXAMPLES q Lznnn / zznz / E / YiAi Example 1: Selection of Bacillus spp. strains in a vigor index platform trial: maize The seed quality component responsible for yield differs among high-germination seed lots and is called seed vigor or seedling vigor. Seed vigor can be affected by seed treatments. To determine the effect of NRRL B-67746 on seed vigor, maize seedling vigor trials were conducted using a paper towel method and a modified protocol from the International Seed Testing Association (ISTA). A standard maize hybrid with 100% hot germination was used in these trials. The seed lot showing the highest seed vigor index is considered more vigorous (Abdul-Baki and Anderson, 1973). Two seedling vigor tests were performed. NRRL B-67746 was compared to other Bacillus strains in the Bacillus amyloliquefaciens operational group as a seed treatment. All strains not derived from commercial products were cultured under the same conditions in a soybean-based medium. Specifically, the strains were cultured at 30 °C for 5 days until sporulation was complete using shaking flasks and a soybean-based medium. In the first experiment, maize seeds were treated with a complete broth of NRRL B-67746 and another Bacillus strain from the Bacillus amyloliquefaciens operational group (Strain 1) at rates of 1 x 10⁶ or 1 x 10⁷ CFU per seed. For comparison, the seeds were also treated with a commercial biological product based on a Bacillus strain from the Bacillus amyloliquefaciens operational group (the Commercial Biological Product), also at a rate of 1 x 10⁶ or 1 x 10⁷ CFU per seed. Seeds treated with water were used as an untreated control. In this experiment, the seedling vigor index was highest for NRRL B-67746 at a rate of 1 x 10⁶ CFU per seed, compared to the untreated control and the other Bacillus strain from the Bacillus amyloliquefaciens operational group. At this rate, the seedling vigor index for NRRL B-67746 was similar to that of the Commercial Biological Product.At a rate of 1 x 10⁷ CFU per seed, NRRL B-67746 showed the highest seedling vigor index compared to all other treatments, which was 70% higher than the untreated control. See Table 1 for the results. q Lznnn / zznz / E / YiAi Table 1 - Seed treatments Treatments Seedling Vigor Index % Increase over Control Untreated Control (water “treatment” only) 12840.83 - Commercial Biological Product (1 × 10⁶ CFU / seed) 14490.62 13.0 Commercial Biological Product (1 × 10⁷ CFU / seed) 15280.97 19.0 NRRL B-67746 (1 × 10⁶ CFU / seed) 14913.30 16.0 NRRL B-67746 (1 × 10⁷ CFU / seed) 21807.52 70.0 ECLAC (1 × 10⁶ CFU / seed) 9511.14 -25.0 ECLAC (1 × 10⁷ CFU / seed) 11003.87 -14.0 ο ίζηηη / ζζηζ / Ε / γίΛΐ In a second experiment, the seeds were treated with (i) a standard chemical coating consisting of a fungicide and an insecticide (referred to in this example as the base chemical) or (ii) with the base chemical and NRRL B-67746 or the Commercial Biological Product, each applied at a rate of 1 x 10⁶ CFU per seed. Five seeds were planted for each treatment, with ten replicates each, on autoclave germination paper (Anchor Company, Minnesota, USA) in a completely randomized design and incubated in a growth chamber at 28 °C. After 7 days, the number of germinated seeds was counted, and the percentage of the total seeds in each group that germinated was calculated. Seedling length was measured by recording the length of the shoots and roots of each plant. The seedling vigor index was calculated using the following formula: germination (%) × seedling length (cm). The commercial biological product and NRRL B-67746 were compared to a commercial chemical seed treatment. In this experiment, as in the previous one, NRRL B-67746 outperformed both the commercial biological product and the control in seedling vigor index. See the results below in Table 2. Table 2 - Seed treatment with basic chemical Treatments Seedling Vigor Index % Increase over Control Control (basic chemical only) 30842.74 - Commercial Biological Product 33094.81 7.0 NRRL B-67746 36097.73 17 Example 2: Analysis of Bacillus spp. strains to detect early vigor: soybeans and corn In a greenhouse experiment, maize and soybean seeds were treated with NRRL B-67746 or other Bacillus strains from the Bacillus amyloliquefaciens operational group to evaluate their effect on plant growth promotion. The treatments consisted of an untreated control and four different strains, including NRRL B-67746, Strain 1, another strain from the Bacillus amyloliquefaciens operational group (Strain 2), and the Commercial Biological Product. Complete broth cultures of NRRL B-67746, Strain 1, and Strain 2 were prepared as described above in Example 1. Each was applied to the seeds at a rate of 1 × 10⁶ CFU / seed. The untreated control (UTC) consisted of seeds treated with sterile deionized water. The seeds were planted in a loamy-sandy soil in 2.5-cm square pots with 12 replicates per variety. A randomized block design was used. During the experiment, the plants were watered from above as needed and fertilized at 7 and 14 days with 2020-20 fertilizer at 1 g / L, 10 mL per pot. The pots were removed from the trays and placed in the randomized design directly on the bench of the greenhouse chamber. The greenhouse chamber was set at 75–80°F with a 14 / 10 hour photoperiod. 21 days after planting, plant growth promotion was assessed by cutting the shoots and measuring the leaf area with a LI-3000C portable leaf area meter (LI-COR® Biosciences, Lincoln, Nebraska, USA). The average leaf areas of soybeans and corn treated with NRRL B-67746 were significantly larger than those of untreated control seeds or seeds treated with Strain 1 or Strain 2.The Commercial Biological Product showed a similar leaf area in corn and a slightly higher leaf area than NRRL B-67746 in soybeans. The results are shown below in Table 3. o Lznnn / zznz / E / YiAi Table 3 - Results of plant growth promotion Treatment Crop-Maize (Total Leaf Surface Area cm2 / plant) n=12 Crop-Soybean (Total Leaf Surface Area cm2 / plant) n=12 Untreated Control 45.07 48.03 Commercial Biological Product 50.37 58.98 NRRL B-67746 50.45 55.07 Strain 1 43.53 45.95 Strain 2 42.02 43.25 Example 3: Nodule mass and plant growth after treatment with Bradyrhizobium and NRRL B-67746 Biological nitrogen fixation by the soybean symbiont Bradyrhizobium japonicum is an important biofertilizer input for soybeans in North and South America. Therefore, it is important to evaluate whether an added biological treatment affects the efficiency of nodulation provided by Bradyrhizobium, as assessed by nodule mass and overall plant growth. In another experiment, soybean seeds were treated with a chemical base consisting of an insecticide and a fungicide typical of North America (NA) or South America (SA), applied in combination with a commercially available Bradyrhizobium inoculant capable of biological nitrogen fixation. The resulting plants were compared to plants grown from seeds treated with the same chemical base, Bradyrhizobium, and a complete broth culture of NRRL B-67746, cultivated as described above in Example 1.The Bradyrhizobium inoculant and B-67746 were each applied at a rate of 1 x 10⁶ CFU / seed. After 28 days of growth, several plant characteristics were evaluated. Plants treated with NRRL B-67746, Bradyrhizobium, and the chemical base showed greater plant height, leaf area, and average root surface area compared to those treated with the chemical base and Bradyrhizobium alone. Table 4 - Nodule mass and plant growth characteristics after the treatment with a base treatment + / - NRRL B-67746 Treatment 0 Fresh Nodule Mass (g / plant) % Increase over Control Plant Height, 28 Days after Planting (cm) % Increase over Control Average Leaf Surface Area (cm2 / plant) % Increase over Control Average Root Surface Area (cm2 / plant) % Increase over Base Chemical Control (NA) + Bradyrhizobium 0.10 9.95 72 47.66 Base chemical (NA) + Bradyrhizo bium + B-67746 0.11 10% 10.2 3% 74 3% 45.45 -5% Base chemical (SA) + Bradyrhizo bium 0.20 14.4 72 135 Base chemical (SA) + Bradyrhizo bium + B-67746 0.22 10% 17 18% 111 54% 135 0% q Lznnn / zznz / E / YiAi Example 4 qPCR studies to identify the presence of NRRL- B-67746 in soybean nodules Soybean plants were treated with 1 × 10⁶ CFU / mL of a commercially available Bradyrhizobium inoculant, alone or in combination with NRRL B-67746 at 1 × 10⁶ CFU / mL. Soybean nodules were randomly selected from the inoculated plants after four weeks. The collected nodules were surface-sterilized with a 1% bleach solution for 5 minutes, followed by 70% ethanol for 1 minute, and then rinsed with water. The nodules were passed over a flame for sterilization and then rinsed three times with sterile distilled water. The nodules were briefly vortexed in 100 pL of ddH₂O and then 100 pL of water were added to check for microbial growth or contamination.The presence of NRRL B-67746 within soybean nodules was determined by grinding the nodules separately into sterilized 1.5 mL microtubes, followed by DNA extraction and qPCR using primer sets designed to be specific for NRRL B-67746 and Bradyrhizobium. Table 5 shows the detection of NRRL B-67746 in several nodules tested separately. Table 5 - Detection of NRRL B-67746 in nodules Treatment Contamination (Y / N) Concentration in nanodroplets (ng / pL) Bradyrhizobium Detection (Y / N) NRRL B-67746 Detection (Y / N) NRRL B-67746 N 35.57 YY NRRL B-67746 N 27.88 YY NRRL B-67746 N 28.76 YY NRRL B-67746 N 2.983 Y Below cutoff NRRL B-67746 N 79.65 YY NRRL B-67746 N 2.629 Y Below cutoff Control N 235.8 YN Control N 304 YN Control N 294.3 YN q Lznnn / zznz / E / YiAi Example 5: Improving the efficiency of nitrogen fixation and assimilation in soybean plants Soybean seeds were treated with NRRL B-67746 and a commercially available Bradyrhizobium japonicum inoculant and tested to determine if this treatment improved nitrogen fixation and assimilation efficiency in soybean plants. Complete broth cultures of NRRL B-67746 were prepared by transferring a colony from a plate to 50 mL of tryptic soybean broth (TSB) in a 250 mL partitioned flask. The inoculated flask was incubated at 30°C and 220 rpm for 24 hours. Then, 1 mL of this seed flask was transferred to 50 mL of Schaeffer TSB medium in a 250 mL partitioned flask and incubated at 30°C and 220 rpm for 72 hours. A small portion of this sample was evaluated for colony-forming units. Soybean seeds were treated with 1 x 106 CFU of complete broth culture of B-67746 per seed.A 1:100 dilution of the Bradyrhizobium strain culture was applied by soaking the seeds directly at planting. Control seeds were treated only with the Bradyrhizobium soak. Nitrogenase Method: Days after planting, roots were harvested from two-week-old soybean seedlings by cutting the entire root system (above the primary root). The roots were washed with water and dried with a paper towel. The roots were placed in a 50 mL Falcon tube and covered with a rubber septum. Five milliliters of acetylene were injected into the tube. The samples were incubated for 1 h before gas chromatograph (GC) injection. Ten milliliters of gas from the headspace in the tube were injected into the GC. Ethylene production was monitored at 0 h, 1 h, and 3 h of acetylene incubation. The results are provided in Table 6 below. Seeds treated with NRRL B-67746 showed significantly higher nitrogenase activity compared to the Bradyrhizobium base treatment. o Lznnn / zznz / E / YiAi Table 6 - Nitrogenase activity for seeds treated with NRRL B-67746 Soybean Variety Average SE B-67746 + Bradyrhizobium Variety 1 237.1825927 109.4159 Bradyrhizobium Only Variety 1 87.15976517 32.6298 B-67746 + Bradyrhizobium Variety 2 77.54834969 34.57229 Bradyrhizobium Only Variety 2 46.42325835 1.728181 Ureidos method Extraction Fresh, six-week-old soybean plants were harvested, and the nodules, root, stem, and petiole were separated. Each plant part was ground in a mortar with liquid nitrogen. 500 mg of freshly ground samples were mixed in 200 mL of 0.5 N NaOH and 300 mL of water. The samples were heated at 100 °C for 8 minutes. After cooling, 200 mL of 0.65 N HCl were added, and the mixture was heated for an additional 8 minutes at 100 °C. After cooling, the mixture was centrifuged for 15 minutes at 17,000 g. Color development 100 mL of supernatant and 500 mL of water were mixed with 100 mL of phenylhydrazine and allowed to stand for 30 minutes or more at room temperature. The tubes were cooled to 0 °C in an ice-water bath, and 500 mL of concentrated HCl, previously cooled to -20 °C, and 100 mL of ferricyanide solution were added. The tubes were then placed at room temperature, and the color was read at 535 nm after 15 minutes. The results are shown in Figure 1. Soybean seedlings treated with NRRL B-67746 had significantly higher ureid content in various parts of the plant compared to the control treatments. Example 6: Field trials in maize Over the course of three years, field trials were conducted in maize to compare the yield-enhancing capabilities of several Bacillus strains within the Bacillus amyloliquefaciens operational group. All non-commercial strains were cultured at 30°C for 5 days until sporulation was complete using shaking flasks and a soybean-based medium. The resulting complete broths were applied to the maize seed along with a basic chemical treatment or a basic chemical and biological treatment, as applicable for each trial. In year 3, a preservative was added to the complete broth before application to the maize seed. The complete broths were applied to the seeds at the following ratios: 1–2 × 10⁶ CFU / seed for years 1 and 2, and 2 × 10⁶ CFU / seed for year 3. The treated maize seeds were planted and grown during the normal growing season until harvest. In each trial, seeds treated with the strains listed in the following tables were compared to a treatment that had all the same components except the strain. There were generally four plots per trial, but in a few trials in year 2, there were three plots per trial. A completely randomized block design (CRBD) was used for all trials. Data from outliers, such as plots with extremely low yields or extreme outliers within the yield range for each trial, were removed from the trial data. Table 7 below shows the performance of NRRL-B-67746 compared to other strains in the same operational group when applied on a chemical basis. The results are based in part on modeling the raw data.The model estimates accounted for spatial variation and stochasticity within fields and were generated using linear mixed models with a constrained maximum probability. This is a standard method used in many studies and produces more accurate results than simply summarizing raw data. Some raw data are also presented to illustrate the differences between raw and modeled data. For example, the raw data show a large yield increase for Strain 5, but the modeled data are more predictive because they account for the small number of trials for Strain 5 and field variations. Although the yield increases for B-67746 are numerically different from the other treatments, the results are not statistically significant.However, this is quite common when comparing multiple trials over several years, even with modeling, due to differences within fields and between trials and years. Therefore, Table 7 also shows the Consistency between trials, which is the rate at which the treatment resulted in a yield increase compared to the control (chemical basis or biological reference chemical basis). Consistency 0.5 and Consistency 2.5 are the rates at which the treatment resulted in a 0.5% or 2.5% yield increase, respectively, compared to the control. This is a common way for agronomists to analyze the effectiveness of different treatments. Predicted Consistency is the modeled version of this raw data. Confidence intervals (CIs) are also provided in Tables 7 and 8 for predicted consistency.The lower 95% confidence interval (CI95) states that the yield increase for the new trials would not fall below this rate, with 95% confidence. The upper 95% CI95 states that the yield increase in the new trials would not exceed this rate, with 95% confidence. Table 7 Strain 2 B6774 6 Strain 1 Strain 3 Base chemical Strain 4 Product Biological product or Strain 5 Strain 6 Number of Tests 63 58 50 29 68 21 21 10 10 Consistency 0 (%) 63.5 74.1 64 58.6 0 52.4 57.1 80 80 Consistency 0.5 (%) 41.3 55.2 36 31 0 23.8 23.8 20 20 Consistency 2.5 (%) 23.8 24.1 12 10.3 0 4.8 9.5 0 0.2 Predicted Consistency 0 (%) 62.5 71.6 63.8 60.5 N / A 58.4 66.4 63.2 66.4 Lower 95% CI for Expected Consistency 0 (%) 52.9 62.3 53.1 46.1 N / A 41.5 49.8 38.9 42.2 Upper 95% CI 71.4 79.6 73.6 73.6 N / A 73.9 80.2 83.1 85.2 For Expected Consistency 0 (%) Average Performance Increase (Raw) 1.23 9 2.635 0.69 2 1.32 7 0 0.05 1 2.159 11.59 7 3.83 6 Standard Error of Performance Increase (Raw) 9.01 6 9.633 9.63 4 9.31 3 8.739 9.17 7 8.223 5.891 5.92 Average Performance Increase (Modeled) 1.42 5 2.131 1.16 1 1.10 3 0 0.58 5 1.092 0.433 1.32 9 Standard Error of Performance Increase (Modeled) 5.94 8 5.926 6.46 9 6.81 5 5.484 6.48 6.48 5.029 5.03 7 Table 8 below shows the performance of NRRL-B-67746 compared to other strains in the same operational group when applied on a chemical and biological reference basis. The same type of data is presented as in Table 7, except that raw yield increases are not provided. Table 8 Chemical and Biological Basis B-67746 Strain 2 Strain 1 Number of Tests 70 32 16 16 Consistency 0 (%) 0 46.9 43.8 56.2 Consistency 0.5 (%) 0 28.1 18.8 25 q ίζηηη / ζζηζ / Ε / γίΛΐ Consistency 2.5 (%) 0 3.1 6.2 0 Expected Consistency 0 (%) N / A 56.7 48.4 57.2 Lower 95% Confidence Interval for Expected Consistency 0 (%) N / A 42.9 29.8 37.9 Upper 95% Confidence Interval for Expected Consistency 0 (%) N / A 69.7 67.3 74.9 Average Performance Increase (Modeled) 0 0.379 -0.158 0.318 Standard Error of Performance Increase (Modeled) 6.151 6.247 5.877 5.886 q ίζηηη / ζζηζ / Ε / γίΛΐ Example 7: Yield benefit in corn field trials Maize field trials were conducted over five years (including the three years evaluated in Example 6) to assess the effect of the NRRL B-67746 strain on maize yield. In years 1 and 2, NRRL B-67746 was cultured at 30°C for 5 days until sporulation was complete using shake flasks and a soybean-based medium. In years 3 and 4, NRRL B-67746 was cultured under the same conditions for 2 days using a bioreactor. In year 5, NRRL B-67746 was cultured under the same conditions for 2 days using a bioreactor and a yeast extract-based medium. The resulting complete broths were applied to hybrid maize seeds along with a base fungicide and insecticide treatment at a rate of 1–2 × 10⁶ CFU / seed for years 1 and 2; 2 × 10⁶ CFU / seed for years 3–5. An additional rate of 1 × 10⁷ CFU / seed was also used in year 5. In years 3–5, a preservative was added to the complete broth before application to the maize seeds. Hybrid maize seeds treated only with the base fungicides and insecticides were included in the trials as controls. The treated hybrid maize seeds were planted and grown in 4-row plots, 30–40 feet long, each year in a variety of geographic maize-growing locations following standard farming practices until harvest. The trials used a completely randomized block design. Each trial consisted of different treatments.Typically, there were four replicates for each treatment, including the control by location. One germplasm was tested in each trial every year, although the germplasm could change from year to year. The relative maturity of the tested germplasm was adjusted for geographic location. At harvest, corn plants were harvested from the two middle rows of each four-row plot to measure yield and avoid edge effects. Yield measurements from individual plots were combined. Data from outliers, such as plots with extremely low yields or extreme outliers within the yield range for each trial, were removed from the trial data. Table 9 presents the results of the year-over-year and location-over-location analysis of yield changes (delta) in corn plants grown from hybrid corn seeds treated with the NRRL B-67746 strain relative to control plants treated only with the base pesticides. The results were based in part on modeling the raw data.The model estimates accounted for spatial variation and stochasticity within and between fields, and were generated using linear mixed models with a constrained maximum probability. This is a standard method used in many studies and produces more accurate results than simply summarizing raw data. Table 9 - Yield increase of maize plants grown from seeds treated with NRRL B-67746 relative to plants grown from control seeds or Lznnn / zznz / E / YiAi Locations Delta* Yield (Bushel / acre) Gain Rate** (%) p-value Number of Trials All 2.0 61 0.09 147 *: Delta yield: represents the change in yield in bushels per acre relative to the control treated with the base pesticides. **: Gain rate: % of fields in which the treatment performance was higher than the control performance. As shown in Table 9, NRRL B-67746 resulted in a yield increase of 2 bushels / acre in a total of 147 trials over five years with a gain rate of 61% compared to the control treated with base pesticides only. Example 8: NRRL B-67746 improved nutrient uptake in corn plants grown in controlled environments To evaluate the effect of NRRL B-67746 on nutrient uptake, hybrid maize seeds treated with NRRL B-67746 complete broth at a rate of 2 × 10⁶ CFU per seed or water (as a control) were planted on a base fungicide and insecticide treatment in sandy soil in 5-inch-high pots and grown in a greenhouse or growth chamber in two separate studies. Plants were grown in the greenhouse with a photoperiod of 16 hours day / 8 hours night, a daytime temperature of 29–33°C and a nighttime temperature of 20°C, and a relative humidity of 52–59%; or in the growth chamber with a photoperiod of 16 hours day / 8 hours night, a daytime temperature of 28°C and a nighttime temperature of 18°C, and a relative humidity of 55%.The plants were irrigated by sub-irrigation at least once a day and fertilized with a 20-20-20 fertilizer twice: at the beginning of the V3 stage and at the end of the V3 stage. The experiments used a completely randomized block design and contained 16 plants per treatment. The second fully expanded leaf from the top of each plant was harvested at the V3 stage for plants grown in the growth chamber and at the V4 stage for plants grown in the greenhouse. The pooled samples were processed, divided into 4 replicates, and subjected to nutrient analysis using standard methods known in the art (for the nitrogen assay: http: / / www.elementar.de / en / products / nprotein-analysis / rapid-nexceed.html; for other nutrients, Havlin, JL, and PN Soltanpour. 1980. A nitric acid plant tissue digest method for use with inductively coupled plasma spectrometry. Comm. Soil Sci. Plant Anal. 11(10):969-980. Modification with the addition of hydrogen peroxide during digestion, determination by inductively coupled plasma optical emission spectrometry (ICP-OES)).Overall, maize plants grown from seeds treated with NRRL B67746 showed increased uptake of all nutrients relative to control plants grown from seeds treated with water and base pesticides, as shown in Table 10. In both studies, significant increases in total nitrogen, calcium, and manganese content were consistently observed, while in one of the studies, significant increases in the uptake of sulfur, magnesium, zinc, iron, copper, and boron were also observed. q Lznnn / zznz / E / YiAi Table 10 - Improvement in nutrient uptake in maize plants grown from seeds treated with NRRL B-67746 in relation to plants grown from control seeds q Lznnn / zznz / E / YiAi Controlled Environment % Increase over Control Total Nitrogen Phosphorus Potassium Sulfur Calcium Magnesium Zinc Iron Manganese Copper Boron Greenhouse 12* 6 3 3 21** 13 9 7 28* 0 8 Growth Chamber 16** 13 14 35* 17* 26* 28 ** 33* 22* 32* 43* *: p value <0.1 **: p value <0.2 Example 9: NRRL B-67746 improved nutrient uptake in soybean plants grown in controlled environments To evaluate the effect of NRRL B-67746 on nutrient uptake, soybean seeds treated with NRRL B-67746 complete broth at a rate of 2 × 10⁶ CFU per seed or water (as a control) were planted on a base fungicide and insecticide treatment in sandy loam soil in 5-inch-high pots and grown in a greenhouse or growth chamber in two separate studies. Plants were grown in the greenhouse with a photoperiod of 16 hours day / 8 hours night, a daytime temperature of 29–33°C and a nighttime temperature of 20°C, and a relative humidity of 52–59%; or in the growth chamber with a photoperiod of 16 hours day / 8 hours night, a daytime temperature of 28°C and a nighttime temperature of 18°C, and a relative humidity of 55%.The plants were irrigated by sub-irrigation at least once a day and fertilized with a 20-20-20 fertilizer twice: at the beginning of the V3 stage and at the end of the V3 stage. The experiments used a completely randomized block design and contained 16 plants per treatment. The second fully expanded leaf from the top of each plant was harvested at the V3 stage for plants grown in the growth chamber and at the V4 stage for plants grown in the greenhouse. The pooled samples were processed, divided into 4 replicates, and subjected to nutrient analysis using standard methods known in the art (for the nitrogen assay: http: / / www.elementar.de / en / products / nprotein-analysis / rapid-nexceed.html; for other nutrients, Havlin, JL, and PN Soltanpour. 1980. A nitric acid plant tissue digest method for use with inductively coupled plasma spectrometry. Comm. Solí Sci. Plant Anal. 11(10):969-980. Modification with the addition of hydrogen peroxide during digestion, determination by inductively coupled plasma optical emission spectrometry (ICP-OES)).Overall, soybean plants grown from seeds treated with NRRL B67746 showed increased uptake of all nutrients compared to control plants grown from seeds treated with water and base pesticides, as shown in Table 11. In one of the studies, significant increases in total contents of nitrogen, potassium, calcium, manganese, sulfur, magnesium, zinc, and iron were observed. Table 11 - Improvement of nutrient uptake in soybean plants grown from seeds treated with NRRL B-67746 in relation to plants grown from control seeds q Lznnn / zznz / E / YiAi Amble nte Control ado % Increase over Control Total Nitrogen Phosphorus Potassium Sulfur Calcium Magnesium Zinc Iron Manganese Copper Boron Greenhouse 22** 13 25** 19** 20** 21** 11 ** 24** 12** 30 13 Growth Chamber 9 2 5 4 2 2 12 18 6 5 2 **: p-value <0.2 Example 10: NRRL B-67746 improved root growth in corn and soybean plants grown in controlled environments Corn and soybean seeds treated with NRRL B-67746 complete broth at a rate of 2 × 10⁶ CFU per seed or water (as a control) were planted on a base treatment of fungicide and insecticide, and grown in a greenhouse or growth chamber as described in Examples 9 and 10. The experiments used a completely randomized block design and contained 16 plants per treatment. Whole plants were harvested at the V3 stage in the growth chamber or the V4 stage in the greenhouse and thoroughly washed with water to remove any soil residue from the roots. The roots of each plant were collected and weighed. The results are summarized in Table 12. Root biomass is expressed as grams of fresh root weight. The control represents plants grown from seeds treated with water over a base fungicide and insecticide treatment. B-67746 represents plants grown from seeds treated with strain B-67734 in addition to the base fungicide and insecticide treatment. Treatment with B-67746 significantly improved the root biomass of maize plants in both greenhouse and growth chamber-grown plants (Table 12). A similar improvement was also observed in soybean plants, although the improvement in growth chamber-grown plants was numerical. q Lznnn / zznz / E / YiAi Table 12 - NRRL B-67746 improved root biomass in corn and soybean plants Controlled Environment Crop Treatment Mean Fresh Root Biomass (g / plant) Standard Error p-value (Comparison with Control) Corn GH Control 10.89 0.39 B-67746 12.36 0.76 0.1 Growth Chamber Control 1.86 0.1 B-67746 2.43 0.13 2.00 x 103 Soybean GH Control 4.32 0.17 B-67746 5.1 0.19 5.00 x W3 Growth Chamber Control 0.13 0.01 B-67746 0.15 0.01 0.26 Example 11: B-67746 improved the solubilization of inorganic phosphate The NRRL B-67746 was cultured in LB liquid medium at 30°C and 400 rpm for 24 hours. After incubation, 50 pL aliquots of the B-67746 culture were added to each well of a 96-well deep block filled with 950 pL of sterile NBRIY medium (glucose 10 g / L, MgSO4-7 H2O 0.1 g / L, KCl 0.2 g / L, MnSO^fW 0.002 g / L, NaCl 0.2 g / L, (NH4)2SO4 0.5 g / L, bromophenol 0.025 g / L) containing 5 g / L of tricalcium phosphate or 5 g / L of ferric phosphate. The 96 filled well blocks were incubated on a shaker at 302°C and 400 rpm with 85% humidity for 72 hours. At the end of the incubation period, the blocks were sealed with a film plate and centrifuged at 4700 rpm for 10 minutes. A 200 pL aliquot of the supernatant from each well of the block was transferred to a well of a Nunc 96 microplate. The absorbance of the mixture on the OD600 was measured using a plate reader. The experiment was repeated twice, each time with 16 replicates per sample.Uninoculated culture media were used as a control. As shown in Table 13, B-67746 was able to solubilize two different inorganic phosphate sources compared to the control without B-67746, as indicated by a reduction in OD600 absorbance. q Lznnn / zznz / E / YiAi Table 13 NRRL B-67746 improved the solubilization of inorganic phosphate Treatment Type of Phosphate Average Absorbance at OD600 Standard Deviation Control Ferric Phosphate 1.3464 0.2174 Tricalcium Phosphate 1.5017 0.2089 B-67746 Ferric Phosphate 0.5688 0.1108 Tricalcium Phosphate 1.2483 0.0417 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by a person skilled in the art to which this invention pertains. All publications, patents, and patent publications cited herein are incorporated herein in their entirety by reference for all purposes. It is understood that the disclosed invention is not limited to the methodology, protocols, or materials described herein, as these may vary. It is also understood that the terminology used herein is merely to describe particular embodiments and is not intended to limit the scope of the present invention, which is limited only by the appended claims.

Claims

NOVELTY OF THE INVENTION Having described the present invention as above, the following is considered novel and is therefore claimed as property: CLAIMS 1. A composition comprising a biologically pure culture of the Bacillus spp. strain NRRL B-67746 or a mutant with all the identifying characteristics of the strain.

2. The composition according to claim 1, characterized in that the mutant has a greater capacity to promote plant growth compared to the Bacillus spp. strain NRRL B-67746.

3. The composition according to claim 2, characterized in that the mutant has a genomic sequence with a sequence identity greater than 90% of Bacillus spp. NRRL B67746.

4. The composition according to claim 2, characterized in that the mutant has a 16S rRNA sequence having at least 98% sequence identity with the 16S rRNA sequence of the Bacillus spp. strain NRRL B-67746.

5. The composition according to any of claims 1-4, further comprising an agriculturally acceptable carrier.

6. A composition comprising a fermentation product of the Bacillus spp. strain NRRL B-67746 or a mutant of the strain having all the identifying characteristics thereof.

7. The composition according to claim 1 or claim 6, further comprising a formulation ingredient.

8. The composition according to claim 7, characterized in that the formulation ingredient is a thickener.

9. The composition according to claim 6, characterized in that the fermentation product is a liquid concentrate.

10. The composition according to claim 9, characterized in that the liquid concentrate is a fluid suspension.

11. The composition according to claim 9 comprising at least approximately 5 x 1010 CFU strain / mL of the liquid concentrate.

12. The composition according to claim 1 or claim 6 further comprising a Bradyrhizobium inoculant. q Lznnn / zznz / E / YiAi 13. The composition according to claim 1 or claim 6 further comprising a fungicide, an insecticide, a nematicide or a biologically active compound.

14. A method of treating a plant to improve its growth, consisting of applying a composition comprising the Bacillus spp. strain NRRL B-67746 or a mutant derived from the strain having all the identifying characteristics of the strain to the plant, a part of the plant and / or a locus of the plant.

15. The method according to claim 14, characterized in that the composition is a fermentation product of the Bacillus spp. strain NRRL B-67746 or the mutant.

16. The method according to claim 14 or claim 15, which consists of applying the composition to the seed.

17. The method according to claim 16, characterized in that the composition is applied in a ratio of approximately 1 x 10⁵ to approximately 1 x 10⁸ colony forming units (CFU) of the NRRL B-67746 strain or mutant per seed.

18. The method according to claim 14, characterized in that the composition is applied to the soil at a rate of approximately 1 × 1013 to approximately 1 × 1015 colony forming units (CFU) per hectare of the NRRL B-67746 strain or mutant.

19. The method according to any of claims 14 to 18, characterized in that the improved plant growth increases the total plant biomass or plant yield by at least 1%.

20. The method according to any of claims 14 to 18, characterized in that the increased plant growth is the increased absorption of nutrients by the plant.

21. The method according to claim 20, wherein the increase in nutrient uptake by the plant is the increase in nitrogen uptake.

22. The method according to any of the preceding claims, characterized in that the plant is selected from the group consisting of cotton, corn, sorghum, soybeans, and sugar beet.

23. Seed treated with a composition according to claim 1.